202 results on '"Loo BW Jr"'
Search Results
2. Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer.
- Author
-
Kozak MM, Murphy JD, Schipper ML, Donington JS, Zhou L, Whyte RI, Shrager JB, Hoang CD, Bazan J, Maxim PG, Graves EE, Diehn M, Hara WY, Quon A, Le QT, Wakelee HA, Loo BW Jr, Kozak, Margaret M, Murphy, James D, and Schipper, Meike L
- Published
- 2011
- Full Text
- View/download PDF
3. Redefining FLASH RT: the impact of mean dose rate and dose per pulse in the gastrointestinal tract.
- Author
-
Liu K, Waldrop T, Aguilar E, Mims N, Neill D, Delahoussaye A, Li Z, Swanson D, Lin SH, Koong AC, Taniguchi CM, Loo BW Jr, Mitra D, and Schüler E
- Abstract
Background: The understanding of how varying radiation beam parameter settings affect the induction and magnitude of the FLASH effect remains limited., Purpose: We sought to systematically evaluate how the magnitude of radiation-induced gastrointestinal (GI) toxicity (RIGIT) depends on the interplay between mean dose rate (MDR) and dose per pulse (DPP)., Methods: C57BL/6J mice received total abdominal irradiation (11-14 Gy, single fraction) through either conventional irradiation (low DPP and low MDR, CONV) or through various combinations of DPP and MDR up to ultra-high-dose-rate (UHDR) beam conditions. DPPs ranging from 1 Gy to 6 Gy were evaluated while the total dose and MDR (>100 Gy/s) were kept constant; the effects of MDR were evaluated for the range 0.3-1440 Gy/s while the total dose and DPP were kept constant. RIGIT was quantified in non-tumor-bearing mice through the regenerating crypt assay and survival assessment. Tumor response was evaluated through tumor growth delay., Results: Within each tested total dose using a constant MDR (>100 Gy/s), increasing DPP led to an increase in sparing (an increase in number of regenerating crypts), with a more prominent effect seen at 12 and 14 Gy TAI. Interestingly, at DPPs of >4 Gy, similar level of crypt sparing was demonstrated irrespective of the MDR used (from 0.3 to 1440 Gy/s). At a fixed high DPP of 4.7 Gy, survival was equivalently improved relative to CONV irrespective of MDR. However, at a lower DPP of 0.93 Gy, a MDR of 104 Gy/s produced a greater survival effect compared to 0.3 Gy/s. We also confirmed that high DPP, regardless of MDR, produced the same magnitude of tumor growth delay relative to CONV using a clinically relevant melanoma mouse model., Conclusions: This study demonstrates the strong influence that the beam parameter settings have on the magnitude of the FLASH effect. Both high DPP and UHDR appeared independently sufficient to produce FLASH sparing of GI toxicity, while isoeffective tumor response was maintained across all conditions., Competing Interests: Declaration of competing interest Billy W. Loo (BWL) is a cofounder and board member of TibaRay, is a consultant on a clinical trial steering committee for BeiGene, and has received lecture honoraria from Mevion. Steven H. Lin (SHL) has the following disclosures: Grants: STCube pharmaceuticals, Beyond Spring Pharmaceuticals, Nektar Therapeutics; Advisory Board: AstraZeneca, Creatv Microtech; Consultant: XRAD Therapeutics; Cofounder and Stock options: Seek Diagnostics., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
4. First in Human Phase 1 Clinical Trial of Stereotactic Irradiation to Achieve Lung Volume Reduction (SILVR) in Severe Emphysema.
- Author
-
Kamtam DN, Binkley MS, Kapula N, Sadeghi C, Nesbit S, Guo HH, Chang J, Maxim PG, Diehn M, Loo BW Jr, and Shrager JB
- Subjects
- Humans, Aged, Male, Middle Aged, Prospective Studies, Female, Forced Expiratory Volume, Lung radiation effects, Pneumonectomy methods, Treatment Outcome, Lung Neoplasms radiotherapy, Lung Neoplasms pathology, Lung Neoplasms surgery, Body Mass Index, Safety, Radiosurgery methods, Radiosurgery adverse effects, Pulmonary Emphysema surgery, Pulmonary Emphysema radiotherapy
- Abstract
Purpose: Only a subset of patients with severe emphysema qualify for lung volume reduction surgery or endobronchial valves. We previously demonstrated that stereotactic ablative radiation therapy of lung tumors reduces lung volume in treated lobes by creating localized lung fibrosis. We aimed to determine the safety and secondarily explore the efficacy of stereotactic irradiation for lung volume reduction (SILVR) over 18 months after intervention in patients with severe emphysema., Methods and Materials: We conducted a single-arm, prospective clinical trial in eligible patients with severe emphysema treated with unilateral stereotactic ablative radiation therapy (45 Gy in 3 fractions) to a target within the most emphysematous region. The primary outcome was safety in terms of incidence of grade ≥3 adverse events, and the secondary outcome was efficacy., Results: Eight patients received the intervention. Median (range) baseline characteristics were age 73 years (63-78); forced expiratory volume in 1 second percent of predicted value (FEV
1 %) 28.5% (19.0-42.0); diffusing capacity of the lungs for carbon monoxide percent of predicted value 40% (24.0-67.0); and body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index 5.5 (5-9). The incidence of grade ≥3 adverse events was 3 of 8 (37.5%). The relative change in target lobe volume was -23.1% (-1.6 to -41.5) and -26.5% (-20.6 to -40.8) at 6 and 18 months, respectively. The absolute ΔFEV1 % was greater in patients with a BODE index ≤5 versus ≥6 (+12.0% vs -2.0%). The mean baseline lung density (in Hounsfield units, reflecting the amount of preserved parenchyma) within the intermediate dose volume (V60BED3 ) correlated with the absolute change in target lobe volume at 18 months., Conclusions: SILVR appears to be safe, with a signal for efficacy as a novel therapeutic alternative for patients with severe emphysema. SILVR may be most safe and effective in patients with a lower BODE index and/or less parenchymal destruction., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
5. Dosimetric calibration of anatomy-specific ultra-high dose rate electron irradiation platform for preclinical FLASH radiobiology experiments.
- Author
-
Wang J, Melemenidis S, Manjappa R, Viswanathan V, Ashraf RM, Levy K, Skinner LB, Soto LA, Chow S, Lau B, Ko RB, Graves EE, Yu AS, Bush KK, Surucu M, Rankin EB, Loo BW Jr, Schüler E, and Maxim PG
- Abstract
Background: FLASH radiation therapy (RT) offers a promising avenue for the broadening of the therapeutic index. However, to leverage the full potential of FLASH in the clinical setting, an improved understanding of the biological principles involved is critical. This requires the availability of specialized equipment optimized for the delivery of conventional (CONV) and ultra-high dose rate (UHDR) irradiation for preclinical studies. One method to conduct such preclinical radiobiological research involves adapting a clinical linear accelerator configured to deliver both CONV and UHDR irradiation., Purpose: We characterized the dosimetric properties of a clinical linear accelerator configured to deliver ultra-high dose rate irradiation to two anatomic sites in mice and for cell-culture FLASH radiobiology experiments., Methods: Delivered doses of UHDR electron beams were controlled by a microcontroller and relay interfaced with the respiratory gating system. We also produced beam collimators with indexed stereotactic mouse positioning devices to provide anatomically specific preclinical treatments. Treatment delivery was monitored directly with an ionization chamber, and charge measurements were correlated with radiochromic film measurements at the entry surface of the mice. The setup for conventional dose rate irradiation utilized the same collimation system but at increased source-to-surface distance. Monte Carlo simulations and film dosimetry were used to characterize beam properties and dose distributions., Results: The mean electron beam energies before the flattening filter were 18.8 MeV (UHDR) and 17.7 MeV (CONV), with corresponding values at the mouse surface of 17.2 and 16.2 MeV. The charges measured with an external ion chamber were linearly correlated with the mouse entrance dose. The use of relay gating for pulse control initially led to a delivery failure rate of 20% (± 1 pulse); adjustments to account for the linac latency improved this rate to < 1/20. Beam field sizes for two anatomically specific mouse collimators (4 × 4 cm
2 for whole-abdomen and 1.5 × 1.5 cm2 for unilateral lung irradiation) were accurate within < 5% and had low radiation leakage (< 4%). Normalizing the dose at the center of the mouse (∼0.75 cm depth) produced UHDR and CONV doses to the irradiated volumes with > 95% agreement., Conclusion: We successfully configured a clinical linear accelerator for increased output and developed a robust preclinical platform for anatomically specific irradiation, with highly accurate and precise temporal and spatial dose delivery, for both CONV and UHDR irradiation applications., (© 2024 American Association of Physicists in Medicine.)- Published
- 2024
- Full Text
- View/download PDF
6. A multi-institutional study to investigate the sparing effect after whole brain electron FLASH in mice: Reproducibility and temporal evolution of functional, electrophysiological, and neurogenic endpoints.
- Author
-
Drayson OGG, Melemenidis S, Katila N, Viswanathan V, Kramár EA, Zhang R, Kim R, Ru N, Petit B, Dutt S, Manjappa R, Ramish Ashraf M, Lau B, Soto L, Skinner L, Yu AS, Surucu M, Maxim PG, Zebadua-Ballasteros P, Wood MA, Montay-Gruel P, Baulch JE, Vozenin MC, Loo BW Jr, and Limoli CL
- Abstract
Background and Purpose: Ultra-high dose-rate radiotherapy (FLASH) has been shown to mitigate normal tissue toxicities associated with conventional dose rate radiotherapy (CONV) without compromising tumor killing in preclinical models. A prominent challenge in preclinical radiation research, including FLASH, is validating both the physical dosimetry and the biological effects across multiple institutions., Materials and Methods: We previously demonstrated dosimetric reproducibility of two different electron FLASH devices at separate institutions using standardized phantoms and dosimeters. In this study, tumor-free adult female mice were given 10 Gy whole brain FLASH and CONV irradiation at both institutions and evaluated for the reproducibility and temporal evolution of multiple neurobiological endpoints., Results: FLASH sparing of behavioral performance on novel object recognition (4 months post-irradiation) and of electrophysiologic long-term potentiation (LTP, 5 months post-irradiation) was reproduced between institutions. Differences between FLASH and CONV on the endpoints of hippocampal neurogenesis (Sox2, doublecortin), neuroinflammation (microglial activation), and electrophysiology (LTP) were not observed at early times (48 h to 2 weeks), but recovery of immature neurons by 3 weeks was greater with FLASH., Conclusion: In summary, we demonstrated reproducible FLASH sparing effects on the brain between two different beams at two different institutions with validated dosimetry. FLASH sparing effects on the endpoints evaluated manifested at later but not the earliest time points., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. Multi-Institutional Audit of FLASH and Conventional Dosimetry With a 3D Printed Anatomically Realistic Mouse Phantom.
- Author
-
Ashraf MR, Melemenidis S, Liu K, Grilj V, Jansen J, Velasquez B, Connell L, Schulz JB, Bailat C, Libed A, Manjappa R, Dutt S, Soto L, Lau B, Garza A, Larsen W, Skinner L, Yu AS, Surucu M, Graves EE, Maxim PG, Kry SF, Vozenin MC, Schüler E, and Loo BW Jr
- Subjects
- Animals, Mice, Radiometry methods, Radiotherapy Dosage, Polyesters, Electrons, Bone and Bones diagnostic imaging, Bone and Bones radiation effects, Polystyrenes, Acrylic Resins, Butadienes, Phantoms, Imaging, Printing, Three-Dimensional, Tomography, X-Ray Computed, Lung radiation effects, Lung diagnostic imaging
- Abstract
Purpose: We conducted a multi-institutional dosimetric audit between FLASH and conventional dose rate (CONV) electron irradiations by using an anatomically realistic 3-dimensional (3D) printed mouse phantom., Methods and Materials: A computed tomography (CT) scan of a live mouse was used to create a 3D model of bony anatomy, lungs, and soft tissue. A dual-nozzle 3D printer was used to print the mouse phantom using acrylonitrile butadiene styrene (∼1.02 g/cm
3 ) and polylactic acid (∼1.24 g/cm3 ) simultaneously to simulate soft tissue and bone densities, respectively. The lungs were printed separately using lightweight polylactic acid (∼0.64 g/cm3 ). Hounsfield units (HU), densities, and print-to-print stability of the phantoms were assessed. Three institutions were each provided a phantom and each institution performed 2 replicates of irradiations at selected anatomic regions. The average dose difference between FLASH and CONV dose distributions and deviation from the prescribed dose were measured with radiochromic film., Results: Compared with the reference CT scan, CT scans of the phantom demonstrated mass density differences of 0.10 g/cm3 for bone, 0.12 g/cm3 for lung, and 0.03 g/cm3 for soft tissue regions. Differences in HU between phantoms were <10 HU for soft tissue and bone, with lung showing the most variation (54 HU), but with minimal effect on dose distribution (<0.5%). Mean differences between FLASH and CONV decreased from the first to the second replicate (4.3%-1.2%), and differences from the prescribed dose decreased for both CONV (3.6%-2.5%) and FLASH (6.4%-2.7%). Total dose accuracy suggests consistent pulse dose and pulse number, although these were not specifically assessed. Positioning variability was observed, likely due to the absence of robust positioning aids or image guidance., Conclusions: This study marks the first dosimetric audit for FLASH using a nonhomogeneous phantom, challenging conventional calibration practices reliant on homogeneous phantoms. The comparison protocol offers a framework for credentialing multi-institutional studies in FLASH preclinical research to enhance reproducibility of biologic findings., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
8. Integrating Audiovisual Immersion Into Pediatric Radiation Therapy Across Multiple Centers: Methodology, Timeliness, and Cost of the Audiovisual-Assisted Therapeutic Ambience in Radiation Therapy Prospective Multi-Institutional Trial.
- Author
-
Oh J, Skinner L, Gutkin PM, Jiang A, Donaldson SS, Loo BW Jr, Wang YP, Ewongwo A, Bredfeldt JS, Breneman JC, Constine LS, Faught AM, Haas-Kogan D, Holmes JA, Krasin M, Larkin C, Marcus KJ, Maxim PG, McClelland S 3rd, Murphy B, Palmer JD, Perkins SM, Shen CJ, Terezakis S, Bush K, and Hiniker SM
- Abstract
Purpose: The Audiovisual-Assisted Therapeutic Ambience in Radiotherapy (AVATAR) trial was a prospective multicenter study (NCT03991156) examining the combination of video immersion with radiation therapy and was successfully conducted through the collaboration of pediatric radiation oncology teams at 10 institutions independent of any pre-existing consortium. We sought to analyze and report the methodology of trial conception and development, process map, and cost., Methods and Materials: The study enrolled patients aged 3 to 10 years preparing to undergo radiation therapy, integrated the combination of AVATAR-based video immersion with radiation therapy at each institution, and offered AVATAR use as an alternative to anesthesia, with rates of anesthesia use and outcomes of serial standardized anxiety and quality-of-life assessments assessed among the 81 children enrolled. A process map was created based on the trial timeline with the following components: study development time (time from conception of the trial to the accrual of the first patient, including design phase, agreement and approval phase, and site preparation phase), and accrual duration time (time from the first to last accrual). Costs and institutional success rates were calculated., Results: Time from inception of study to last accrual was 3.6 years (1313 days). The study development time was 417 days (31.7%), and accrual duration time was 896 days (68.3%), with the final 50% of accrual occurring in <6 months. Equipment cost was approximately $550 per institution and was covered by funding from the lead study institution. All 10 centers were successful with AVATAR implementation, defined as ≥50% of patients able to avoid anesthesia with the use of AVATAR, including centers with both photon and proton therapy., Conclusions: This report elaborates on the methodology and timeline of trial conception and development using data from a previously published supportive care study combining video immersion with radiation therapy among 10 cooperating pediatric oncology institutions. It highlights the potential for multicenter collaborations on prospective trials integrating supportive care therapies with radiation therapy., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
9. Consequences of ionizing radiation exposure to the cardiovascular system.
- Author
-
Jahng JWS, Little MP, No HJ, Loo BW Jr, and Wu JC
- Abstract
Ionizing radiation is widely used in various industrial and medical applications, resulting in increased exposure for certain populations. Lessons from radiation accidents and occupational exposure have highlighted the cardiovascular and cerebrovascular risks associated with radiation exposure. In addition, radiation therapy for cancer has been linked to numerous cardiovascular complications, depending on the distribution of the dose by volume in the heart and other relevant target tissues in the circulatory system. The manifestation of symptoms is influenced by numerous factors, and distinct cardiac complications have previously been observed in different groups of patients with cancer undergoing radiation therapy. However, in contemporary radiation therapy, advances in treatment planning with conformal radiation delivery have markedly reduced the mean heart dose and volume of exposure, and these variables are therefore no longer sole surrogates for predicting the risk of specific types of heart disease. Nevertheless, certain cardiac substructures remain vulnerable to radiation exposure, necessitating close monitoring. In this Review, we provide a comprehensive overview of the consequences of radiation exposure on the cardiovascular system, drawing insights from various cohorts exposed to uniform, whole-body radiation or to partial-body irradiation, and identify potential risk modifiers in the development of radiation-associated cardiovascular disease., (© 2024. Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
10. Exploring Deep Learning for Estimating the Isoeffective Dose of FLASH Irradiation From Mouse Intestinal Histological Images.
- Author
-
Fu J, Yang Z, Melemenidis S, Viswanathan V, Dutt S, Manjappa R, Lau B, Soto LA, Ashraf MR, Skinner L, Yu SJ, Surucu M, Casey KM, Rankin EB, Graves E, Lu W, Loo BW Jr, and Gu X
- Subjects
- Animals, Mice, Female, Intestines radiation effects, Intestines pathology, Radiotherapy Dosage, Jejunum radiation effects, Jejunum pathology, Proof of Concept Study, Deep Learning, Mice, Inbred C57BL
- Abstract
Purpose: Ultrahigh-dose-rate (FLASH) irradiation has been reported to reduce normal tissue damage compared with conventional dose rate (CONV) irradiation without compromising tumor control. This proof-of-concept study aims to develop a deep learning (DL) approach to quantify the FLASH isoeffective dose (dose of CONV that would be required to produce the same effect as the given physical FLASH dose) with postirradiation mouse intestinal histology images., Methods and Materials: Eighty-four healthy C57BL/6J female mice underwent 16 MeV electron CONV (0.12 Gy/s; n = 41) or FLASH (200 Gy/s; n = 43) single fraction whole abdominal irradiation. Physical dose ranged from 12 to 16 Gy for FLASH and 11 to 15 Gy for CONV in 1 Gy increments. Four days after irradiation, 9 jejunum cross-sections from each mouse were hematoxylin and eosin stained and digitized for histological analysis. CONV data set was randomly split into training (n = 33) and testing (n = 8) data sets. ResNet101-based DL models were retrained using the CONV training data set to estimate the dose based on histological features. The classical manual crypt counting (CC) approach was implemented for model comparison. Cross-section-wise mean squared error was computed to evaluate the dose estimation accuracy of both approaches. The validated DL model was applied to the FLASH data set to map the physical FLASH dose into the isoeffective dose., Results: The DL model achieved a cross-section-wise mean squared error of 0.20 Gy
2 on the CONV testing data set compared with 0.40 Gy2 of the CC approach. Isoeffective doses estimated by the DL model for FLASH doses of 12, 13, 14, 15, and 16 Gy were 12.19 ± 0.46, 12.54 ± 0.37, 12.69 ± 0.26, 12.84 ± 0.26, and 13.03 ± 0.28 Gy, respectively., Conclusions: Our proposed DL model achieved accurate CONV dose estimation. The DL model results indicate that in the physical dose range of 13 to 16 Gy, the biologic dose response of small intestinal tissue to FLASH irradiation is represented by a lower isoeffective dose compared with the physical dose. Our DL approach can be a tool for studying isoeffective doses of other radiation dose modifying interventions., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
11. Chest wall pain after single-fraction thoracic stereotactic ablative Radiotherapy: Dosimetric analysis from the iSABR trial.
- Author
-
Lau B, Wu YF, Cui S, Fu J, Jackson S, Pham D, Dubrowski P, Eswarappa S, Skinner L, Shirato H, Taguchi H, Gensheimer MF, Gee H, Chin AL, Diehn M, Loo BW Jr, Moiseenko V, and Vitzthum LK
- Subjects
- Humans, Female, Male, Aged, Prospective Studies, Middle Aged, Aged, 80 and over, Radiotherapy Dosage, Thoracic Neoplasms radiotherapy, Dose-Response Relationship, Radiation, Radiosurgery adverse effects, Radiosurgery methods, Thoracic Wall radiation effects, Chest Pain etiology
- Abstract
Background and Purpose: Concerns over chest wall toxicity has led to debates on treating tumors adjacent to the chest wall with single-fraction stereotactic ablative radiotherapy (SABR). We performed a secondary analysis of patients treated on the prospective iSABR trial to determine the incidence and grade of chest wall pain and modeled dose-response to guide radiation planning and estimate risk., Materials and Methods: This analysis included 99 tumors in 92 patients that were treated with 25 Gy in one fraction on the iSABR trial which individualized dose by tumor size and location. Toxicity events were prospectively collected and graded based on the CTCAE version 4. Dose-response modeling was performed using a logistic model with maximum likelihood method utilized for parameter fitting., Results: There were 22 grade 1 or higher chest wall pain events, including five grade 2 events and zero grade 3 or higher events. The volume receiving at least 11 Gy (V
11Gy ) and the minimum dose to the hottest 2 cc (D2cc ) were most highly correlated with toxicity. When dichotomized by an estimated incidence of ≥ 20 % toxicity, the D2cc > 17 Gy (36.6 % vs. 3.7 %, p < 0.01) and V11Gy > 28 cc (40.0 % vs. 8.1 %, p < 0.01) constraints were predictive of chest wall pain, including among a subset of patients with tumors abutting or adjacent to the chest wall., Conclusion: For small, peripheral tumors, single-fraction SABR is associated with modest rates of low-grade chest wall pain. Proximity to the chest wall may not contraindicate single fractionation when using highly conformal, image-guided techniques with sharp dose gradients., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: B.L., Y.F.W., S.C., J.F., S.J., P.D., H.G., V.M., S.E., H.S., and A.L.C. report no disclosures. L.S. reports US patent: 16/809427. D.P. reports disclosures including a grant with RefleXion Medical Research. H.T. reports a contract with the Global Center for Biomedical Science and Engineering at Hokkaido University. M.F.G. reports disclosures including grants with Varian Medical Systems and stock holdings with Roche. M.Diehnreports disclosures including research support from AstraZeneca and Varian Medical Systems, royalties for patent licenses from Roche and Foresight Diagnostics, consulting fees from AstraZeneca, Boehringer Ingelheim, Genentech, Gritstone Bio, Illumina, and Regeneron, honoraria from Bristol Myers Squibb and Novartis, leadership as a board member of Foresight Diagnostics, and stock/options for CiberMed, Gritstone Bio, and Foresight Diagnostics. B.W.L. reports disclosures including grants with Varian Medical Systems, leadership as a board member of TibaRay, and stock holdings in TibaRay. L.K.V. reports disclosures including grants from RefleXion Medical., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
12. Navigating the Critical Translational Questions for Implementing FLASH in the Clinic.
- Author
-
Loo BW Jr, Verginadis II, Sørensen BS, Mascia AE, Perentesis JP, Koong AC, Schüler E, Rankin EB, Maxim PG, Limoli CL, and Vozenin MC
- Subjects
- Humans, Animals, Radiation Oncology methods, Clinical Trials as Topic, Neoplasms radiotherapy, Translational Research, Biomedical
- Abstract
The "FLASH effect" is an increased therapeutic index, that is, reduced normal tissue toxicity for a given degree of anti-cancer efficacy, produced by ultra-rapid irradiation delivered on time scales orders of magnitude shorter than currently conventional in the clinic for the same doses. This phenomenon has been observed in numerous preclinical in vivo tumor and normal tissue models. While the underlying biological mechanism(s) remain to be elucidated, a path to clinical implementation of FLASH can be paved by addressing several critical translational questions. Technological questions pertinent to each beam type (eg, electron, proton, photon) also dictate the logical progression of experimentation required to move forward in safe and decisive clinical trials. Here we review the available preclinical data pertaining to these questions and how they may inform strategies for FLASH cancer therapy clinical trials., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
13. Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.
- Author
-
Hui C, Brown E, Wong S, Das M, Wakelee H, Neal J, Ramchandran K, Myall NJ, Pham D, Xing L, Yang Y, Kovalchuk N, Yuan Y, Lu Y, Xiang M, Chin A, Diehn M, Loo BW Jr, and Vitzthum LK
- Subjects
- Humans, Adolescent, Bayes Theorem, Chemoradiotherapy methods, Lung, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Clinical Trials, Phase II as Topic, Clinical Trials, Phase I as Topic, Lung Neoplasms drug therapy, Carcinoma, Non-Small-Cell Lung drug therapy
- Abstract
Introduction: Prior attempts to escalate radiation dose for non-small cell lung cancer (NSCLC) have not improved survival. Given the high risk for cardiopulmonary toxicity with treatment and heterogenous presentation of locally advanced NSCLC, it is unlikely that a single dose regimen is optimal for all patients. This phase I/II trial aims to evaluate a novel treatment approach where the level of accelerated hypofractionation is determined by the predicted toxicity from dose to organs at risk (OARs)., Methods: Patients ≥ 18 years old with lung cancer planned for fractionated radiotherapy to the lung with concurrent chemotherapy will be eligible. Radiation therapy (RT) will be delivered to a total dose of 60 to 66 Gy in 30, 25, or 20 fractions depending on the ability to meet constraints to key organs at risk including the lungs, heart, and esophagus. The primary endpoint is high grade pulmonary, esophageal, or cardiac toxicity. A Bayesian optimized design is used to determine stopping boundaries and evaluate the primary endpoint., Conclusion: PACER will evaluate the safety and feasibility of personalized accelerated chemoradiotherapy for lung cancer., Competing Interests: Disclosure Billy W Loo: co-founder and board member of TibaRay and a consultant on a clinical trial steering committee of Beigene, and has received lecture honorarium from Mevion; Joel W Neal: ASCO; Millie Das: consulting with Genentech and Eurofins; participation on the advisory board for AstraZeneca, Beigene, Sanofi/Genzyme, and Janssen; and research with Merck, Genentech, CellSight, Novartis, AbbVie, United Therapeutics, Verily, Varian Medical Systems and Celgene. Heather Wakelee: grants with ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, Bristol-Myers Squibb, Clovis Oncology, Genentech/Roche, Merck, Novartis, SeaGen, Xcovery, and Helsinn; participation on the advisory board for AstraZeneca, Blueprint, Mirati, Merck, and Genentech/Roche; and leadership with International Association for the Study of Lung Cancer and ECOG-ACRIN; Maximilian Diehn: grants with Varian, Genentech, and AstraZeneca; royalties for patent license with Roche and Foresight Diagnostics; consulting fees with Roche Sequencing Solutions, Varian, BioNTech, RefleXion, Novartis, Illumina, Genentech, BioNTech, Boehringer Ingelheim, and Gritstone Oncology; patents with Roche, Foresight Diagnostics, and Celgene; participation on the advisory board for AstraZeneca, Genentech, Boehringer Ingel- heim, Illumina, and Gritstrone; leadership as a board member of Foresight Diagnostics; stock holdings with Foresight Diagnostics and CiberMed; and in-kin research from Illumina; Lucas Vitzthum: grants from RefleXion Medical; Mohona Roy: Speakers' Bureau: MJH Life Sciences; Research Funding: Varian Medical Systems (Inst); Nathaniel Myall: Honoraria: Patient Power; Kavitha Ramchandran: Consulting or Advisory Role: Drishti, GroupWell, Varian Medical Systems. The remaining authors declare no conflict of interest., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
14. Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.
- Author
-
Hui C, Marquez C, Lau B, Das M, Myall NJ, Roy M, Wakelee HA, Neal JW, Kovalchuk N, Chin A, Diehn M, Loo BW Jr, Xiang M, and Vitzthum LK
- Subjects
- Humans, Radiation Dose Hypofractionation, Retrospective Studies, Prospective Studies, Patient Selection, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy
- Abstract
Purpose/objectives: Adoption of hypofractionated accelerated radiation therapy (HART) with concurrent chemotherapy has been limited by toxicity concerns. We aimed to describe outcomes of patients treated with HART and concurrent chemotherapy and to evaluate dosimetry to organs at risk to guide patient selection., Materials/methods: We evaluated a retrospective cohort of NSCLC patients treated with concurrent chemotherapy with HART (>2.2 Gy per fraction) or standard fractionated radiation therapy (SFRT; 2-2.2 Gy fractions). Dosimetric parameters to key organs at risk were compared, and toxicity, patterns of recurrence and survival were calculated for the cohorts., Results: Fifty-three patients treated with HART were compared with 100 patients treated with SFRT. Median dose per fraction for the HART cohort was 2.75 Gy (range 2.4-3 Gy). HART patients had significantly lower doses to the lung, heart, and esophagus due to patient selection. The HART group and had rates of grade 2+ pneumonitis (9.4 vs. 19%, P = .16) and grade 2+ esophagitis (20.8 vs. 45%, P < .01) that compared favorably to SFRT. Cumulative incidence of in-field recurrence trended lower in the HART cohort (7.6% vs. 23.1%, P = .058). Among the HART group, 88.7% (47/53) met the newly proposed lung constraints based on the degree of hypofractionation CONCLUSION: In select patients with favorable dosimetry to organs at risk, definitive HART with concurrent chemotherapy achieved excellent local control with low toxicity. These results are being used to inform a prospective study on the safety and efficacy of HART with concurrent chemotherapy for select NSCLC patients., Competing Interests: Disclosure Billy W Loo: co-founder and board member of TibaRay and a consultant on a clinical trial steering committee of Beigene, and has received lecture honorarium from Mevion; Joel W Neal: ASCO; Millie Das: consulting with Genentech and Eurofins; participation on the advisory board for AstraZeneca, Beigene, Sanofi/Genzyme, and Janssen; and research with Merck, Genentech, CellSight, Novartis, AbbVie, United Therapeutics, Verily, Varian Medical Systems and Celgene; Heather Wakelee: grants with ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, Bristol-Myers Squibb, Clovis Oncology, Genentech/Roche, Merck, Novartis, SeaGen, Xcovery, and Helsinn; participation on the advisory board for AstraZeneca, Blueprint, Mirati, Merck, and Genentech/Roche; and leadership with International Association for the Study of Lung Cancer and ECOG-ACRIN; Maximilian Diehn: grants with Varian, Genentech, and AstraZeneca; royalties for patent license with Roche and Foresight Diagnostics; consulting fees with Roche Sequencing Solutions, Varian, BioNTech, RefleXion, Novartis, Illumina, Genentech, BioNTech, Boehringer Ingelheim, and Gritstone Oncology; patents with Roche, Foresight Diagnostics, and Celgene; participation on the advisory board for AstraZeneca, Genentech, Boehringer Ingel- heim, Illumina, and Gritstrone; leadership as a board member of Foresight Diagnostics; stock holdings with Foresight Diagnostics and CiberMed; and in-kin research from Illumina; Lucas Vitzthum: grants from RefleXion Medical; Mohona Roy: Speakers' Bureau: MJH Life Sciences; Research Funding: Varian Medical Systems (Inst) Nathaniel Myall: Honoraria: Patient Power The remaining authors declare no conflict of interest., (Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
15. Pulmonary interstitial lymphography: A prospective trial with potential impact on stereotactic ablative radiotherapy planning for early-stage lung cancer.
- Author
-
Ko RB, Abelson JA, Fleischmann D, Louie JD, Hwang GL, Sze DY, Schüler E, Kielar KN, Maxim PG, Le QT, Hara WH, Diehn M, Kothary N, and Loo BW Jr
- Subjects
- Humans, Lung, Lymphography, Prospective Studies, Feasibility Studies, Lung Neoplasms diagnostic imaging, Lung Neoplasms radiotherapy, Lung Neoplasms surgery, Radiosurgery
- Abstract
This prospective feasibility trial investigated pulmonary interstitial lymphography to identify thoracic primary nodal drainage (PND). A post-hoc analysis of nodal recurrences was compared with PND for patients with early-stage lung cancer; larger studies are needed to establish correlation. Exploratory PND-inclusive stereotactic ablative radiotherapy plans were assessed for dosimetric feasibility., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
16. FLASH-RT does not affect chromosome translocations and junction structures beyond that of CONV-RT dose-rates.
- Author
-
Barghouth PG, Melemenidis S, Montay-Gruel P, Ollivier J, Viswanathan V, Jorge PG, Soto LA, Lau BC, Sadeghi C, Edlabadkar A, Zhang R, Ru N, Baulch JE, Manjappa R, Wang J, Le Bouteiller M, Surucu M, Yu A, Bush K, Skinner L, Maxim PG, Loo BW Jr, Limoli CL, Vozenin MC, and Frock RL
- Abstract
Background and Purpose: The impact of radiotherapy (RT) at ultra high vs conventional dose rate (FLASH vs CONV) on the generation and repair of DNA double strand breaks (DSBs) is an important question that remains to be investigated. Here, we tested the hypothesis as to whether FLASH-RT generates decreased chromosomal translocations compared to CONV-RT., Materials and Methods: We used two FLASH validated electron beams and high-throughput rejoin and genome-wide translocation sequencing (HTGTS-JoinT-seq), employing S. aureus and S. pyogenes Cas9 "bait" DNA double strand breaks (DSBs) in HEK239T cells, to measure differences in bait-proximal repair and their genome-wide translocations to "prey" DSBs generated after various irradiation doses, dose rates and oxygen tensions (normoxic, 21% O
2 ; physiological, 4% O2 ; hypoxic, 2% and 0.5% O2 ). Electron irradiation was delivered using a FLASH capable Varian Trilogy and the eRT6/Oriatron at CONV (0.08-0.13 Gy/s) and FLASH (1x102 -5x106 Gy/s) dose rates. Related experiments using clonogenic survival and γH2AX foci in the 293T and the U87 glioblastoma lines were also performed to discern FLASH-RT vs CONV-RT DSB effects., Results: Normoxic and physioxic irradiation of HEK293T cells increased translocations at the cost of decreasing bait-proximal repair but were indistinguishable between CONV-RT and FLASH-RT. Although no apparent increase in chromosome translocations was observed with hypoxia-induced apoptosis, the combined decrease in oxygen tension with IR dose-rate modulation did not reveal significant differences in the level of translocations nor in their junction structures. Furthermore, RT dose rate modality on U87 cells did not change γH2AX foci numbers at 1- and 24-hours post-irradiation nor did this affect 293T clonogenic survival., Conclusion: Irrespective of oxygen tension, FLASH-RT produces translocations and junction structures at levels and proportions that are indistinguishable from CONV-RT., Competing Interests: Declaration of Competing Interest BWL Jr. has received research support outside this work from Varian Medical Systems, is a co-founder and board member of TibaRay, and is a consultant on a clinical trial steering committee for BeiGene. PGM is a co-founder of TibaRay. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
17. Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
- Author
-
Gensheimer MF, Gee H, Shirato H, Taguchi H, Snyder JM, Chin AL, Vitzthum LK, Maxim PG, Wakelee HA, Neal J, Das M, Chang DT, Kidd E, Hancock SL, Shultz DB, Horst KC, Le QT, Wong S, Brown E, Nguyen N, Liang R, Loo BW Jr, and Diehn M
- Subjects
- Humans, Male, Aged, Female, Retrospective Studies, Treatment Outcome, Lung Neoplasms pathology, Carcinoma, Non-Small-Cell Lung pathology, Radiosurgery adverse effects, Radiosurgery methods
- Abstract
Importance: Stereotactic ablative radiotherapy (SABR) is used for treating lung tumors but can cause toxic effects, including life-threatening damage to central structures. Retrospective data suggested that small tumors up to 10 cm3 in volume can be well controlled with a biologically effective dose less than 100 Gy., Objective: To assess whether individualizing lung SABR dose and fractionation by tumor size, location, and histological characteristics may be associated with local tumor control., Design, Setting, and Participants: This nonrandomized controlled trial (the iSABR trial, so named for individualized SABR) was a phase 2 multicenter trial enrolling participants from November 15, 2011, to December 5, 2018, at academic medical centers in the US and Japan. Data were analyzed from December 9, 2020, to May 10, 2023. Patients were enrolled in 3 groups according to cancer type: initial diagnosis of non-small cell lung cancer (NSCLC) with an American Joint Committee on Cancer 7th edition T1-3N0M0 tumor (group 1), a T1-3N0M0 new primary NSCLC with a history of prior NSCLC or multiple NSCLCs (group 2), or lung metastases from NSCLC or another solid tumor (group 3)., Intervention: Up to 4 tumors were treated with once-daily SABR. The dose ranged from 25 Gy in 1 fraction for peripheral tumors with a volume of 0 to 10 cm3 to 60 Gy in 8 fractions for central tumors with a volume greater than 30 cm3., Main Outcome: Per-group freedom from local recurrence (same-lobe recurrence) at 1 year, with censoring at time of distant recurrence, death, or loss to follow-up., Results: In total, 217 unique patients (median [IQR] age, 72 [64-80] years; 129 [59%] male; 150 [69%] current or former smokers) were enrolled (some multiple times). There were 240 treatment courses: 79 in group 1, 82 in group 2, and 79 in group 3. A total of 285 tumors (211 [74%] peripheral and 74 [26%] central) were treated. The most common dose was 25 Gy in 1 fraction (158 tumors). The median (range) follow-up period was 33 (2-109) months, and the median overall survival was 59 (95% CI, 49-82) months. Freedom from local recurrence at 1 year was 97% (90% CI, 91%-99%) for group 1, 94% (90% CI, 87%-97%) for group 2, and 96% (90% CI, 89%-98%) for group 3. Freedom from local recurrence at 5 years ranged from 83% to 93% in the 3 groups. The proportion of patients with grade 3 to 5 toxic effects was low, at 5% (including a single patient [1%] with grade 5 toxic effects)., Conclusions and Relevance: The results of this nonrandomized controlled trial suggest that individualized SABR (iSABR) used to treat lung tumors may allow minimization of treatment dose and is associated with excellent local control. Individualized dosing should be considered for use in future trials., Trial Registration: ClinicalTrials.gov Identifier: NCT01463423.
- Published
- 2023
- Full Text
- View/download PDF
18. Predicting Adverse Cardiac Events After Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
- Author
-
No HJ, Guo FB, Park NJ, Kastelowitz N, Rhee JW, Clark DE, Chin AL, Vitzthum LK, Horst KC, Moding EJ, Loo BW Jr, Diehn M, and Binkley MS
- Abstract
Background: Radiotherapy may cause grade ≥3 cardiac events, necessitating a better understanding of risk factors. The potential predictive role of imaging biomarkers with radiotherapy doses for cardiac event occurrence has not been studied., Objectives: The aim of this study was to establish the associations between cardiac substructure dose and coronary artery calcium (CAC) scores and cardiac event occurrence., Methods: A retrospective cohort analysis included patients with locally advanced non-small cell lung cancer treated with radiotherapy (2006-2018). Cardiac substructures, including the left anterior descending coronary artery, left main coronary artery, left circumflex coronary artery, right coronary artery, and TotalLeft (left anterior descending, left main, and left circumflex coronary arteries), were contoured. Doses were measured in 2-Gy equivalent units, and visual CAC scoring was compared with automated scoring. Grade ≥3 adverse cardiac events were recorded. Time-dependent receiver-operating characteristic modeling, the log-rank statistic, and competing-risk models were used to measure prediction performance, threshold modeling, and the cumulative incidence of cardiac events, respectively., Results: Of the 233 eligible patients, 61.4% were men, with a median age of 68.1 years (range: 34.9-90.7 years). The median follow-up period was 73.7 months (range: 1.6-153.9 months). Following radiotherapy, 22.3% experienced cardiac events, within a median time of 21.5 months (range: 1.7-118.9 months). Visual CAC scoring showed significant correlation with automated scoring ( r = 0.72; P < 0.001). In a competing-risk multivariable model, TotalLeft volume receiving 15 Gy (per 1 cc; HR: 1.38; 95% CI: 1.11-1.72; P = 0.004) and CAC score >5 (HR: 2.51; 95% CI: 1.08-5.86; P = 0.033) were independently associated with cardiac events. A model incorporating age, TotalLeft CAC (score >5), and volume receiving 15 Gy demonstrated a higher incidence of cardiac events for a high-risk group (28.9%) compared with a low-risk group (6.9%) ( P < 0.001)., Conclusions: Adverse cardiac events associated with radiation occur in more than 20% of patients undergoing thoracic radiotherapy within a median time of <2 years. The present findings provide further evidence to support significant associations between TotalLeft radiotherapy dose and cardiac events and define CAC as a predictive risk factor., Competing Interests: This work was supported by a Radiological Society of North America Research & Education Foundation Resident Research Grant. Dr No has received research grant funding from the Radiological Society of North America. Dr Kastelowitz has received research grant funding from the American Society for Radiation Oncology–LUNGevity and the Radiological Society of North America; and has received consulting fees from MIM Software. Dr Rhee has received funding from the National Institutes of Health (grant K08-HL148540); and has conducted industry-sponsored research for Pfizer. Dr Clark has received research grant funding from the Adult Congenital Heart Association. Dr Vitzthum has received research grants from RefleXion. Dr Loo has received research grants from the National Institutes of Health (grant P01CA244091) and Varian Medical Systems; holds stock in TibaRay; and is a board member for TibaRay. Dr Diehn has received research grant funding from Varian, Genentech, and AstraZeneca; receives royalties for patent licenses from Roche and Foresight Diagnostics; has received consulting fees from Roche, Varian, BioNTech, RefleXion, Novartis, Illumina, Genentech, Boehringer Ingelheim, and Gritstone Oncology; licenses patents to Roche and Foresight Diagnostics for liquid biopsy methods and to Celgene for single-cell analysis methods; is on advisory boards for AstraZeneca, Genentech, Boehringer Ingelheim, Illumina, and Gritstone Oncology; is a board member for Foresight Diagnostics; holds stock in Foresight Diagnostics and CiberMed; and receives in-kind research reagents from Illumina. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
19. Clinical Linear Accelerator-Based Electron FLASH: Pathway for Practical Translation to FLASH Clinical Trials.
- Author
-
No HJ, Wu YF, Dworkin ML, Manjappa R, Skinner L, Ashraf MR, Lau B, Melemenidis S, Viswanathan V, Yu AS, Surucu M, Schüler E, Graves EE, Maxim PG, and Loo BW Jr
- Subjects
- Humans, Radiometry methods, Particle Accelerators, Radiotherapy Planning, Computer-Assisted methods, Radiotherapy Dosage, Electrons, Neoplasms
- Abstract
Purpose: Ultrahigh-dose-rate (UHDR) radiation therapy (RT) has produced the FLASH effect in preclinical models: reduced toxicity with comparable tumor control compared with conventional-dose-rate RT. Early clinical trials focused on UHDR RT feasibility using specialized devices. We explore the technical feasibility of practical electron UHDR RT on a standard clinical linear accelerator (LINAC)., Methods and Materials: We tuned the program board of a decommissioned electron energy for UHDR electron delivery on a clinical LINAC without hardware modification. Pulse delivery was controlled using the respiratory gating interface. A short source-to-surface distance (SSD) electron setup with a standard scattering foil was configured and tested on an anthropomorphic phantom using circular blocks with 3- to 20-cm field sizes. Dosimetry was evaluated using radiochromic film and an ion chamber profiler., Results: UHDR open-field mean dose rates at 100, 80, 70, and 59 cm SSD were 36.82, 59.52, 82.01, and 112.83 Gy/s, respectively. At 80 cm SSD, mean dose rate was ∼60 Gy/s for all collimated field sizes, with an R80 depth of 6.1 cm corresponding to an energy of 17.5 MeV. Heterogeneity was <5.0% with asymmetry of 2.2% to 6.2%. The short SSD setup was feasible under realistic treatment conditions simulating broad clinical indications on an anthropomorphic phantom., Conclusions: Short SSD and tuning for high electron beam current on a standard clinical LINAC can deliver flat, homogenous UHDR electrons over a broad, clinically relevant range of field sizes and depths with practical working distances in a configuration easily reversible to standard clinical use., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
20. Shielding Analysis of a Preclinical Bremsstrahlung X-ray FLASH Radiotherapy System within a Clinical Radiation Therapy Vault.
- Author
-
Rosenstrom A, Santana-Leitner M, Rokni S, Shumail M, Tantawi S, Kwofie J, Dewji S, and Loo BW Jr
- Subjects
- Humans, X-Rays, Radiography, Polyethylene, Monte Carlo Method, Particle Accelerators, Neutrons, Photons therapeutic use, Radiation Oncology
- Abstract
Abstract: A preclinical radiotherapy system producing FLASH dose rates with 12 MV bremsstrahlung x rays is being developed at Stanford University and SLAC National Accelerator Laboratory. Because of the high expected workload of 6,800 Gy w -1 at the isocenter, an efficient shielding methodology is needed to protect operators and the public while the preclinical system is operated in a radiation therapy vault designed for 6 MV x rays. In this study, an analysis is performed to assess the shielding of the local treatment head and radiation vault using the Monte Carlo code FLUKA and the empirical methodology given in the National Council on Radiation Protection and Measurements Report 151. Two different treatment head shielding designs were created to compare single-layer and multilayer shielding methodologies using high-Z and low-Z materials. The multilayered shielding methodology produced designs with a 17% reduction in neutron fluence leaking from the treatment head compared to the single layered design of the same size, resulting in a decreased effective dose to operators and the public. The conservative assumptions used in the empirical methods can lead to over-shielding when treatment heads use polyethylene or multilayered shielding. High-Z/Low-Z multilayered shielding optimized via Monte Carlo is shown to be effective in the case of treatment head shielding and provide more effective shielding design for external beam radiotherapy systems that use 12 MV bremsstrahlung photons. Modifications to empirical methods used in the assessment of MV radiotherapy systems may be warranted to capture the effects of polyethylene in treatment head shielding., (Copyright © 2023 Health Physics Society.)
- Published
- 2023
- Full Text
- View/download PDF
21. Unilateral Diaphragmatic Paralysis After Stereotactic Ablative Radiation Therapy to a Lung Tumor Abutting the Course of the Phrenic Nerve.
- Author
-
Eke I, Guo HH, Loo BW Jr, Sung AW, Diehn M, Vitzthum L, Chin AL, and Gensheimer MF
- Subjects
- Female, Humans, Phrenic Nerve pathology, Disease Progression, Respiratory Paralysis etiology, Lung Neoplasms pathology, Radiosurgery adverse effects
- Abstract
We present the case of a woman with metastatic adenoid cystic carcinoma who received stereotactic ablative radiation therapy with a total dose of 50 Gy in 4 fractions to 2 lung metastases and developed symptomatic left phrenic nerve injury 2 years after radiation. The maximum dose to the approximate location of the phrenic nerve was 57.7 Gy, which corresponds to a biologically effective dose for late effects (using α/β ratio = 3) of 335.14 Gy. Here, we discuss the case, planning considerations by radiation oncologists and medical physicists, and the multidisciplinary medical management of this patient., (Copyright © 2023 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
22. Feasibility of the Audio-Visual Assisted Therapeutic Ambience in Radiotherapy (AVATAR) System for Anesthesia Avoidance in Pediatric Patients: A Multicenter Trial.
- Author
-
Gutkin PM, Skinner L, Jiang A, Donaldson SS, Loo BW Jr, Oh J, Wang YP, von Eyben R, Snyder J, Bredfeldt JS, Breneman JC, Constine LS, Faught AM, Haas-Kogan D, Holmes JA, Krasin M, Larkin C, Marcus KJ, Maxim PG, McClelland S 3rd, Murphy B, Palmer JD, Perkins SM, Shen CJ, Terezakis S, Bush K, and Hiniker SM
- Subjects
- Humans, Child, Child, Preschool, Feasibility Studies, Prospective Studies, Quality of Life, Radiation Oncology, Anesthesia
- Abstract
Purpose: The Audio-Visual Assisted Therapeutic Ambience in Radiotherapy (AVATAR) system was the first published radiation therapy (RT)-compatible system to reduce the need for pediatric anesthesia through video-based distraction. We evaluated the feasibility of AVATAR implementation and effects on anesthesia use, quality of life, and anxiety in a multicenter pediatric trial., Methods and Materials: Pediatric patients 3 to 10 years of age preparing to undergo RT at 10 institutions were prospectively enrolled. Children able to undergo at least 1 fraction of RT using AVATAR without anesthesia were considered successful (S). Patients requiring anesthesia for their entire treatment course were nonsuccessful (NS). The PedsQL3.0 Cancer Module (PedsQL) survey assessed quality of life and was administered to the patient and guardian at RT simulation, midway through RT, and at final treatment. The modified Yale Preoperative Anxiety Scale (mYPAS) assessed anxiety and was performed at the same 3 time points. Success was evaluated using the χ
2 test. PedsQL and mYPAS scores were assessed using mixed effects models with time points evaluated as fixed effects and a random intercept on the subject., Results: Eighty-one children were included; median age was 7 years. AVATAR was successful at all 10 institutions and with photon and proton RT. There were 63 (78%) S patients; anesthesia was avoided for a median of 20 fractions per patient. Success differed by age (P = .04) and private versus public insurance (P < .001). Both patient (P = .008) and parent (P = .006) PedsQL scores significantly improved over the course of RT for patients aged 5 to 7. Anxiety in the treatment room decreased for both S and NS patients over RT course (P < .001), by age (P < .001), and by S versus NS patients (P < .001)., Conclusions: In this 10-center prospective trial, anesthesia avoidance with AVATAR was 78% in children aged 3 to 10 years, higher than among age-matched historical controls (49%; P < .001). AVATAR implementation is feasible across multiple institutions and should be further studied and made available to patients who may benefit from video-based distraction., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
23. The sparing effect of FLASH-RT on synaptic plasticity is maintained in mice with standard fractionation.
- Author
-
Limoli CL, Kramár EA, Almeida A, Petit B, Grilj V, Baulch JE, Ballesteros-Zebadua P, Loo BW Jr, Wood MA, and Vozenin MC
- Subjects
- Mice, Animals, Hippocampus physiology, Synaptic Transmission physiology, Neuronal Plasticity physiology, Long-Term Potentiation physiology
- Abstract
Long-term potentiation (LTP) was used to gauge the impact of conventional and FLASH dose rates on synaptic transmission. Data collected from the hippocampus and medial prefrontal cortex confirmed significant inhibition of LTP after 10 fractions of 3 Gy (30 Gy total) conventional radiotherapy. Remarkably, 10x3Gy FLASH radiotherapy and unirradiated controls were identical and exhibited normal LTP., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. Framework for Quality Assurance of Ultrahigh Dose Rate Clinical Trials Investigating FLASH Effects and Current Technology Gaps.
- Author
-
Zou W, Zhang R, Schüler E, Taylor PA, Mascia AE, Diffenderfer ES, Zhao T, Ayan AS, Sharma M, Yu SJ, Lu W, Bosch WR, Tsien C, Surucu M, Pollard-Larkin JM, Schuemann J, Moros EG, Bazalova-Carter M, Gladstone DJ, Li H, Simone CB 2nd, Petersson K, Kry SF, Maity A, Loo BW Jr, Dong L, Maxim PG, Xiao Y, and Buchsbaum JC
- Subjects
- Humans, Health Facilities, Patient Positioning, Technology, Radiotherapy Dosage, Credentialing, Electrons
- Abstract
FLASH radiation therapy (FLASH-RT), delivered with ultrahigh dose rate (UHDR), may allow patients to be treated with less normal tissue toxicity for a given tumor dose compared with currently used conventional dose rate. Clinical trials are being carried out and are needed to test whether this improved therapeutic ratio can be achieved clinically. During the clinical trials, quality assurance and credentialing of equipment and participating sites, particularly pertaining to UHDR-specific aspects, will be crucial for the validity of the outcomes of such trials. This report represents an initial framework proposed by the NRG Oncology Center for Innovation in Radiation Oncology FLASH working group on quality assurance of potential UHDR clinical trials and reviews current technology gaps to overcome. An important but separate consideration is the appropriate design of trials to most effectively answer clinical and scientific questions about FLASH. This paper begins with an overview of UHDR RT delivery methods. UHDR beam delivery parameters are then covered, with a focus on electron and proton modalities. The definition and control of safe UHDR beam delivery and current and needed dosimetry technologies are reviewed and discussed. System and site credentialing for large, multi-institution trials are reviewed. Quality assurance is then discussed, and new requirements are presented for treatment system standard analysis, patient positioning, and treatment planning. The tables and figures in this paper are meant to serve as reference points as we move toward FLASH-RT clinical trial performance. Some major questions regarding FLASH-RT are discussed, and next steps in this field are proposed. FLASH-RT has potential but is associated with significant risks and complexities. We need to redefine optimization to focus not only on the dose but also on the dose rate in a manner that is robust and understandable and that can be prescribed, validated, and confirmed in real time. Robust patient safety systems and access to treatment data will be critical as FLASH-RT moves into the clinical trials., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
25. Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Antiangiogenic Agents.
- Author
-
Lau BC, Wu YF, No HJ, Ko RB, Devine MD, Das MS, Neal JW, Wakelee HA, Ramchandran K, Gensheimer MF, Diehn M, Chin AL, Loo BW Jr, and Vitzthum LK
- Subjects
- Humans, Angiogenesis Inhibitors adverse effects, Vascular Endothelial Growth Factor A, Hemorrhage epidemiology, Hemorrhage etiology, Lung Neoplasms pathology, Radiosurgery adverse effects, Radiosurgery methods
- Abstract
Introduction: Severe pulmonary hemorrhage can occur in patients treated with thoracic stereotactic ablative radiotherapy (SABR) and vascular endothelial growth factor inhibitors (VEGFis). There is limited understanding of which patients are at risk for toxicity with the combination of thoracic SABR and VEGFis or how the risk differs over either therapy alone., Methods: We evaluated a prospectively maintained cohort of 690 patients with 818 pulmonary tumors treated with highly conformal SABR. Rates of any-grade and grade 3 plus (G3+) pulmonary hemorrhage were compared between patients treated with or without VEGFi therapy across tumor locations. Outcomes were compared between patients treated with SABR plus VEGFi and a propensity-matched cohort of those treated with VEGFi therapy alone., Results: Treatment with VEGFi plus SABR was associated with higher rates of G3+ pulmonary hemorrhage compared with those treated with SABR alone for the overall cohort (3-y incidence: 7.9% versus 0.6%, p < 0.01) and those with central tumors (19.1% versus 3.3%, p = 0.04). When further subdivided, there were significantly higher toxicity rates with VEGFi for the ultracentral (9.0% versus 45.0%, p = 0.044), but not central nonabutting tumors (0.0% versus 1.3%, p = 0.69). There was an increased incidence of G3+ hemorrhage in patients treated with VEGFi plus SABR compared with VEGFi alone (9.6% versus 1.3%, p = 0.04)., Conclusions: The combination of VEGFi and SABR was associated with an increased risk of high-grade pulmonary hemorrhage over either therapy alone. Low rates of toxicity were observed when excluding patients with SABR to ultracentral tumors and applying highly conformal SABR techniques., (Copyright © 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
26. Monte Carlo simulation of shielding designs for a cabinet form factor preclinical MV-energy photon FLASH radiotherapy system.
- Author
-
Rosenstrom A, Santana-Leitner M, Rokni SH, Shumail M, Tantawi S, Dewji S, and Loo BW Jr
- Subjects
- Monte Carlo Method, Computer Simulation, Photons therapeutic use, Polyethylenes
- Abstract
Purpose: A preclinical MV-energy photon FLASH radiotherapy system is being designed at Stanford and SLAC National Accelerator Laboratory. Because of the higher energy and dose rate compared to conventional kV-energy photon laboratory-scale irradiators, adequate shielding in a stand-alone cabinet form factor is more challenging to achieve. We present a Monte Carlo simulation of multilayered shielding for a compact self-shielding system without the need for a radiation therapy vault., Methods: A multilayered shielding approach using multiple alternating layers of high-Z and low-Z materials is applied to the self-shielded cabinet to effectively mitigate the secondary radiation produced and to allow the device to be housed in a Controlled Radiation Area outside of a radiation vault. The multilayered shielding approach takes advantage of the properties of high-Z and low-Z radiation shielding materials such as density, cross-section, atomic number of the shielding elements, and products of radiation interactions within each layer. The Monte Carlo radiation transport code, FLUKA, is used to simulate the total effective dose produced by the operation., Results: The multilayered shielding designs proposed and simulated produced effective dose rates significantly lower than monolayer designs with the same total material thickness at the regulatory boundary; this is accomplished through the manipulation of the locations where secondary radiation is produced and reactions due to material properties such as neutron back reflection in hydrogen. Borated polyethylene at 5 wt% significantly increased the shielding performance as compared to regular polyethylene, with the magnitude of the reduction depending upon the order of the shielding material., Conclusions: The multilayered shielding provides a path for shielding preclinical FLASH systems that deliver MV-energy bremsstrahlung photons. This approach promises to be more efficient with respect to the shielding material mass and space claim as compared to shielded vaults typically required for clinical radiation therapy with MV photons., (© 2023 American Association of Physicists in Medicine.)
- Published
- 2023
- Full Text
- View/download PDF
27. Transformative Technology for FLASH Radiation Therapy.
- Author
-
Schulte R, Johnstone C, Boucher S, Esarey E, Geddes CGR, Kravchenko M, Kutsaev S, Loo BW Jr, Méot F, Mustapha B, Nakamura K, Nanni EA, Obst-Huebl L, Sampayan SE, Schroeder CB, Sheng K, Snijders AM, Snively E, Tantawi SG, and Van Tilborg J
- Abstract
The general concept of radiation therapy used in conventional cancer treatment is to increase the therapeutic index by creating a physical dose differential between tumors and normal tissues through precision dose targeting, image guidance, and radiation beams that deliver a radiation dose with high conformality, e.g., protons and ions. However, the treatment and cure are still limited by normal tissue radiation toxicity, with the corresponding side effects. A fundamentally different paradigm for increasing the therapeutic index of radiation therapy has emerged recently, supported by preclinical research, and based on the FLASH radiation effect. FLASH radiation therapy (FLASH-RT) is an ultra-high-dose-rate delivery of a therapeutic radiation dose within a fraction of a second. Experimental studies have shown that normal tissues seem to be universally spared at these high dose rates, whereas tumors are not. While dose delivery conditions to achieve a FLASH effect are not yet fully characterized, it is currently estimated that doses delivered in less than 200 ms produce normal-tissue-sparing effects, yet effectively kill tumor cells. Despite a great opportunity, there are many technical challenges for the accelerator community to create the required dose rates with novel compact accelerators to ensure the safe delivery of FLASH radiation beams., Competing Interests: Billy W. Loo Jr. is an employee of Stanford University School of Medicine. Dr. Billy W. Loo Jr. has received research support from Varian Medical Systems. He is a co-founder and board member of TibaRay. Reinhard Schulte is employed by Loma Linda University, School of Medicine. Dr. Schulte has received research funding by Grant R44CA257178 “Ultrafast and Precise External Beam Monitor for FLASH and Other Advanced Radiation Therapy Modalities” from the National Cancer Institute awarded to Peter Friedman (PI), Integrated Sensors, LLC. The funder had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The United States Government has rights to patents pursuant to Contract No. DE-AC52–07NA27344 between the United States Department of Energy and Lawrence Livermore National Security, LLC for the operation of Lawrence Livermore National Laboratory. For SES, Opcondys, Inc. is a for-profit company and may profit from the technologies described in this paper.
- Published
- 2023
- Full Text
- View/download PDF
28. Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging.
- Author
-
Alhusaini S, Lanman TA, Ko RB, Therkelsen KE, Eyben RV, Diehn M, Soltys SG, Pollom EL, Chin A, Vitzthum L, Wakelee HA, Padda SK, Ramchandran K, Loo BW Jr, Neal JW, and Nagpal S
- Abstract
Objective: The 2-year incidence of brain metastases (BrMs) in stage III non-small lung cell cancer (NSCLC) has been estimated to be around 30%. However, recent clinical trials have demonstrated considerably lower BrMs rates in this patient population. In this study, we aimed to review the real-world incidence, surveillance, and treatment patterns of BrMs in stage III NSCLC., Materials and Methods: Using a retrospective single-center study design, we identified patients with stage III NSCLC who received radiation with curative intent over a 10-year period. Outcome variables included BrMs incidence, overall survival (OS), and survival from date of BrMs. Additionally, we assessed patterns of BrMs surveillance in stage III NSCLC and treatment., Results: We identified a total of 279 stage III NSCLC patients, of which 160 with adequate records were included in the final analyses [adenocarcinoma (n = 96), squamous cell carcinoma (n = 53), other histology subtype (n = 11)]. The median OS for the entire cohort was 41 months (95% CI, 28-53), while the median time from BrMs to death was 19 months (95% CI, 9-21). Twenty-three patients (14.4%) received planned surveillance brain MRIs at 6, 12, and 24 months after completion of treatment. The remaining 137 patients (85.6%) received brain MRIs at systemic recurrence (restaging) or when neurologically symptomatic. A total of 37 patients (23%) developed BrMs, with a 2-year cumulative BrMs incidence of 17% (95% CI, 11-23). A higher incidence of BrMs was identified in patients with adenocarcinoma relative to those with squamous cell carcinoma ( p < 0.01). Similarly, a higher 2-year BrMs incidence was observed in patients who received planned surveillance brain MRI relative to those who did not, although statistical significance was not reached. Stereotactic radiosurgery (SRS) treated 29 of BrMs patients (78.4%) and was preferred over WBRT, which treated only 3 patients (8.1%)., Conclusions: At our center, BrMs incidence in stage III NSCLC patients was lower than historically reported but notably higher than the incidence described in recent clinical trials. Routine BrMs surveillance potentially allows earlier detection of asymptomatic BrMs. However, asymptomatic BrMs were mostly detected on restaging MRI at the time of recurrence., Competing Interests: Author SS: Speaker Honoraria, Zap Surgical, Inc and consultant at Accuray, Inc. EP: Board, Vysioneer. HW: President of International Association for the Study of Lung Cancer IASLC. Executive committee member of ECOG-ACRIN. Advisory Board, AstraZeneca, Janssen, Daiichi Sankyo, Blueprint, Mirati, Merck, Genentech/Roche. BL: Co-founder and board member of TibaRay. Research support from Varian Medical Systems. JN: Consulting or Advisory Role: AstraZeneca, Genentech/Roche, Exelixis, Jounce Therapeutics, Takeda Pharmaceuticals, Eli Lilly and Company, Calithera Biosciences, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron Pharmaceuticals, Natera, Sanofi/Regeneron, D2G Oncology, Surface Oncology, Turning Point Therapeutics. SN: Consulting Role, Mirati, SeaGen, Biocept. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Author SS received research funding from Novocure, Inc. EP received research funding from Genentech. HW received research funding from ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, BMS, Clovis Oncology, Genentech/Roche, Merck, Novartis, SeaGen, Xcovery, Helsinn. BL received research funding from Varian Medical Systems. JN received research funding from Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GSK, Janssen, AbbVie. SN received research funding from Novocure, PharmAbcine, Berg Health, Agios, Pyramid Biosciences, ABM Therapuetics., (Copyright © 2023 Alhusaini, Lanman, Ko, Therkelsen, Eyben, Diehn, Soltys, Pollom, Chin, Vitzthum, Wakelee, Padda, Ramchandran, Loo, Neal and Nagpal.)
- Published
- 2023
- Full Text
- View/download PDF
29. TopasOpt: An open-source library for optimization with Topas Monte Carlo.
- Author
-
Whelan B, Loo BW Jr, Wang J, and Keall P
- Subjects
- Monte Carlo Method, Bayes Theorem, Computer Simulation, Radiotherapy Dosage, Radiometry methods, Water
- Abstract
Purpose: To describe and test TopasOpt: a free, open-source and extensible library for performing mathematical optimization of Monte Carlo simulations in Topas., Methods: TopasOpt enables any Topas model to be transformed into an optimization problem, and any parameter within the model to be treated as an optimization variable. Three case studies are presented. The starting model consists of a 10 MeV electron beam striking a tungsten target. The resulting bremsstrahlung X-ray spectrum is collimated by a primary and secondary collimator before being scored in a water tank. In the first case study (electron phase space optimization), five parameters describing the electron beam were treated as optimization variables and assigned a random starting value. An objective function was defined based on differences of depth-dose and profiles in water between the original (ground truth) model and a given model generated by TopasOpt. The problem was solved using Bayesian Optimization and the Nelder-Mead method. One hundred iterations were run in each case. In the second case study, (collimator geometry optimization), this process was repeated, but three geometric parameters defining the secondary collimator were treated as optimization variables and assigned random starting values, and forty iterations were run. In the third case study, the optimization was repeated with different number of primary particles to study the effect of noise on convergence., Results: For case 1 (phase space optimization), both optimization algorithms successfully minimized the objective function, with absolute mean differences in profile dose of 0.4% (Bayesian) and 0.3% (Nelder-Mead) and 0.2% in depth-dose for both algorithms. The beam energy was recovered to within 1%, however some parameters had relative errors of up to 171% - a result consistent with the known X-ray dose is insensitivity to many electron beam parameters. For case 2 (geometry optimization), absolute mean differences in profile dose were 0.6% (Bayesian) and 0.9% (Nelder-Mead), and 0.5% and 0.9% in depth-dose. The maximum percentage error in any parameter was 9% with Bayesian Optimization and 28% with Nelder-Mead. Finally, the Bayesian Optimization algorithm was demonstrated to be robust to moderate levels of noise; when the standard deviation of the objective function was 16% of the mean, the maximum error in any parameter value was 16%, and the absolute mean difference in dose was 0.9% (profile) and 0.8% (depth-dose)., Conclusions: An open-source library for optimization with Topas Monte Carlo has been developed, tested, and released. This tool will improve accuracy and efficiency in any situation in which the optimal value of a parameter in a Monte Carlo simulation is unknown. Applications for this tool include (1) The design of new components (2) Reverse engineering of models based on limited experimental or published data, and (3) Tuning of Monte Carlo "hyper parameters" such as variance reduction, physics settings, or scoring parameters., (© 2022 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.)
- Published
- 2023
- Full Text
- View/download PDF
30. Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer.
- Author
-
Devine M, Merriott DJ, No HJ, Lau B, Say C, Yoo C, Yi E, Ko RB, Neal JW, Wakelee HA, Das M, Loo BW Jr, Diehn M, Chin AL, and Vitzthum LK
- Subjects
- Humans, Retrospective Studies, Treatment Outcome, Neoplasm Staging, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms pathology, Small Cell Lung Carcinoma pathology, Radiosurgery adverse effects, Radiosurgery methods
- Abstract
Purpose: Stereotactic ablative radiation therapy (SABR) results in high rates of primary tumor control for early-stage non-small cell lung cancer (NSCLC). For patients with isolated hilar or mediastinal nodal recurrence (INR) after SABR, the optimal salvage treatment strategy is unclear. The purpose of this study was to determine the rate of INR after SABR for early-stage NSCLC and to describe patterns of care and treatment outcomes after salvage therapy., Methods and Materials: This retrospective cohort study included 342 patients with stage T1-3N0M0 NSCLC treated with definitive SABR from 2003 to 2018. We evaluated the incidence of INR and baseline factors between patients who did and did not experience INR. Among patients who experienced INR, we described treatment patterns and outcomes including overall survival (OS) and progression free survival (PFS) from the time of nodal failure using the Kaplan-Meier method., Results: With a median follow-up of 3.3 years, the 3-year INR rate was 10.6% (95% CI, 6.6%-13.4%). Among the 34 patients experiencing INR, the 3-year rates of OS and PFS were 39.3% (24.4%-63.3%) and 26.7% (14.1%-0.3%), respectively. The 34 patients with INR were treated with radiation therapy alone (26.7%), concurrent chemoradiation therapy (43.3%), chemotherapy alone (13.3%), or observation (16.7%). Patients treated with concurrent chemoradiation therapy had the best survival outcomes, with a 3-year OS and PFS of 81.5% (61.1%-100.0%) and 63.9% (40.7%-100.0%), respectively. Of the patients treated with salvage radiation therapy or concurrent chemoradiation therapy, 14.3% experienced grade 3 toxic effects, and no patients had grade ≥4 toxic effects., Conclusions: In this study, INR occurred in approximately 10% of patients treated with SABR for early-stage NSCLC. The highest rates of OS and PFS among patients with INR were observed in those treated with salvage chemoradiation therapy., (Copyright © 2022 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
31. Bayesian optimization to design a novel x-ray shaping device.
- Author
-
Whelan B, Trovati S, Wang J, Fahrig R, Maxim PG, Hanuka A, Shumail M, Tantawi S, Merrick J, Perl J, Keall P, and Loo BW Jr
- Subjects
- Humans, Radiotherapy Dosage, X-Rays, Bayes Theorem, Monte Carlo Method, Radiotherapy Planning, Computer-Assisted methods, Radiotherapy, Intensity-Modulated methods
- Abstract
Purpose: In radiation therapy, x-ray dose must be precisely sculpted to the tumor, while simultaneously avoiding surrounding organs at risk. This requires modulation of x-ray intensity in space and/or time. Typically, this is achieved using a multi leaf collimator (MLC)-a complex mechatronic device comprising over one hundred individually powered tungsten 'leaves' that move in or out of the radiation field as required. Here, an all-electronic x-ray collimation concept with no moving parts is presented, termed "SPHINX": Scanning Pencil-beam High-speed Intensity-modulated X-ray source. SPHINX utilizes a spatially distributed bremsstrahlung target and collimator array in conjunction with magnetic scanning of a high energy electron beam to generate a plurality of small x-ray "beamlets.", Methods: A simulation framework was developed in Topas Monte Carlo incorporating a phase space electron source, transport through user defined magnetic fields, bremsstrahlung x-ray production, transport through a SPHINX collimator, and dose in water. This framework was completely parametric, meaning a simulation could be built and run for any supplied geometric parameters. This functionality was coupled with Bayesian optimization to find the best parameter set based on an objective function which included terms to maximize dose rate for a user defined beamlet width while constraining inter-channel cross talk and electron contamination. Designs for beamlet widths of 5, 7, and 10 mm
2 were generated. Each optimization was run for 300 iterations and took approximately 40 h on a 24-core computer. For the optimized 7-mm model, a simulation of all beamlets in water was carried out including a linear scanning magnet calibration simulation. Finally, a back-of-envelope dose rate formalism was developed and used to estimate dose rate under various conditions., Results: The optimized 5-, 7-, and 10-mm models had beamlet widths of 5.1 , 7.2 , and 10.1 mm2 and dose rates of 3574, 6351, and 10 015 Gy/C, respectively. The reduction in dose rate for smaller beamlet widths is a result of both increased collimation and source occlusion. For the simulation of all beamlets in water, the scanning magnet calibration reduced the offset between the collimator channels and beam centroids from 2.9 ±1.9 mm to 0.01 ±0.03 mm. A slight reduction in dose rate of approximately 2% per degree of scanning angle was observed. Based on a back-of-envelope dose rate formalism, SPHINX in conjunction with next-generation linear accelerators has the potential to achieve substantially higher dose rates than conventional MLC-based delivery, with delivery of an intensity modulated 100 × 100 mm2 field achievable in 0.9 to 10.6 s depending on the beamlet widths used., Conclusions: Bayesian optimization was coupled with Monte Carlo modeling to generate SPHINX geometries for various beamlet widths. A complete Monte Carlo simulation for one of these designs was developed, including electron beam transport of all beamlets through scanning magnets, x-ray production and collimation, and dose in water. These results demonstrate that SPHINX is a promising candidate for sculpting radiation dose with no moving parts, and has the potential to vastly improve both the speed and robustness of radiotherapy delivery. A multi-beam SPHINX system may be a candidate for delivering magavoltage FLASH RT in humans., (© 2022 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.)- Published
- 2022
- Full Text
- View/download PDF
32. Real-time optical oximetry during FLASH radiotherapy using a phosphorescent nanoprobe.
- Author
-
Ha B, Liang K, Liu C, Melemenidis S, Manjappa R, Viswanathan V, Das N, Ashraf R, Lau B, Soto L, Graves EE, Rao J, Loo BW Jr, and Pratx G
- Subjects
- Humans, Radiotherapy Dosage, Radiotherapy, Oximetry, Oxygen
- Abstract
The rapid depletion of oxygen during irradiation at ultra-high dose rate calls for tissue oximeters capable of high temporal resolution. This study demonstrates a water-soluble phosphorescent nanoprobe and fiber-coupled instrument, which together are used to measure the kinetics of oxygen depletion at 200 Hz during irradiation of in vitro solutions., Competing Interests: Declaration of competing interest BWL has received research support from Varian Medical Systems. BWL is a co-founder and board member of TibaRay. Other authors declare that they have no competing interests., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
33. Design and validation of a dosimetric comparison scheme tailored for ultra-high dose-rate electron beams to support multicenter FLASH preclinical studies.
- Author
-
Jorge PG, Melemenidis S, Grilj V, Buchillier T, Manjappa R, Viswanathan V, Gondré M, Vozenin MC, Germond JF, Bochud F, Moeckli R, Limoli C, Skinner L, No HJ, Wu YF, Surucu M, Yu AS, Lau B, Wang J, Schüler E, Bush K, Graves EE, Maxim PG, Loo BW Jr, and Bailat C
- Subjects
- Humans, Phantoms, Imaging, Water, Alanine, Electrons, Radiometry
- Abstract
Background and Purpose: We describe a multicenter cross validation of ultra-high dose rate (UHDR) (>= 40 Gy/s) irradiation in order to bring a dosimetric consensus in absorbed dose to water. UHDR refers to dose rates over 100-1000 times those of conventional clinical beams. UHDR irradiations have been a topic of intense investigation as they have been reported to induce the FLASH effect in which normal tissues exhibit reduced toxicity relative to conventional dose rates. The need to establish optimal beam parameters capable of achieving the in vivo FLASH effect has become paramount. It is therefore necessary to validate and replicate dosimetry across multiple sites conducting UHDR studies with distinct beam configurations and experimental set-ups., Materials and Methods: Using a custom cuboid phantom with a cylindrical cavity (5 mm diameter by 10.4 mm length) designed to contain three type of dosimeters (thermoluminescent dosimeters (TLDs), alanine pellets, and Gafchromic films), irradiations were conducted at expected doses of 7.5 to 16 Gy delivered at UHDR or conventional dose rates using various electron beams at the Radiation Oncology Departments of the CHUV in Lausanne, Switzerland and Stanford University, CA., Results: Data obtained between replicate experiments for all dosimeters were in excellent agreement (±3%). In general, films and TLDs were in closer agreement with each other, while alanine provided the closest match between the expected and measured dose, with certain caveats related to absolute reference dose., Conclusion: In conclusion, successful cross-validation of different electron beams operating under different energies and configurations lays the foundation for establishing dosimetric consensus for UHDR irradiation studies, and, if widely implemented, decrease uncertainty between different sites investigating the mechanistic basis of the FLASH effect., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
34. Detection of Recurrence After Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT.
- Author
-
Sodji QH, Harris JP, Quon A, Modlin LA, Lau B, Jiang A, Trakul N, Maxim PG, Diehn M, Loo BW Jr, and Hiniker SM
- Subjects
- Fluorodeoxyglucose F18, Humans, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals, Retrospective Studies, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms diagnostic imaging, Lung Neoplasms radiotherapy
- Abstract
Introduction/background: Differentiating local recurrence (LR) from post-treatment changes following stereotactic ablative radiotherapy (SABR) for thoracic tumors is challenging. We sought to evaluate the performance of FDG-PET-CT in distinguishing recurrence from post-radiation changes in patients with stage I-II non-small cell lung cancer (NSCLC) treated with SABR., Materials and Methods: We performed a retrospective review of patients with stage I-II NSCLC treated with SABR and subsequently followed with surveillance FDG-PET-CT scans from 2004 to 2014. The radiology reports were coded as 0 or 1 if minimally or substantially concerning for LR, respectively, and correlated with outcome. Prognostic factors for false-positive FDG-PET-CT were assessed using logistic regression models., Results: We identified 145 patients meeting inclusion criteria for the retrospective analysis. Amongst the 39 (26.9%) patients with FDG-PET-CT scans concerning for LR 3 to 24 months after treatment, 14 were confirmed to have LR. Thus, the positive predictive value (PPV) of FDG-PET-CT in identifying LR was 36% (14/39). Factors associated with a false-positive scan included concerning FDG-PET-CT at the earliest post-treatment time point (3 months) (odds ratio 0.67, P= .04) and older age (odds ratio 2.3, P= .02)., Conclusion: Our analysis indicates that the PPV of a concerning FDG-PET-CT after SABR for early-stage NSCLC is relatively low, especially at early post-treatment timepoints, but accuracy is improving over time with institutional experience., Competing Interests: Conflicts of Interest The authors declare no conflicts of interest related to this work. B.W.L. has received research support from Varian Medical Systems, and is a co-founder and board member of TibaRay. M.D. has received research support from Varian Medical Systems, Illumina, AstraZeneca; paid consultancy from Roche, AstraZeneca, BioNTech, RefleXion, Genentech, Illumina, Gritstone Oncology, Novartis, Boehringer Ingelheim; travel honoraria from Roche and stock options from Foresight Diagnostics, CiberMed. All other authors have none., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
35. Acute and Late Esophageal Toxicity After SABR to Thoracic Tumors Near or Abutting the Esophagus.
- Author
-
Sodji QH, Ko R, von Eyben R, Owen SG, Capaldi DPI, Bush K, Binkley MS, Alrowais F, Pickthorn B, Maxim PG, Gensheimer MF, Diehn M, and Loo BW Jr
- Subjects
- Humans, Radiotherapy Dosage, Esophagitis etiology, Lung Neoplasms pathology, Radiosurgery methods, Thoracic Neoplasms complications
- Abstract
Purpose: Our purpose was to evaluate the incidence of acute and late esophageal toxicity in patients with thoracic tumors near or abutting the esophagus treated with SABR., Methods and Materials: Among patients with thoracic tumors treated with SABR, we identified those with tumors near or abutting the esophagus. Using the linear-quadratic model with an α/ß ratio of 10, we determined the correlation between dosimetric parameters and esophageal toxicity graded using the Common Terminology Criteria for Adverse Events, version 5.0., Results: Out of 2200 patients treated with thoracic SABR, 767 patients were analyzable for esophageal dosimetry. We identified 55 patients with tumors near the esophagus (52 evaluable for esophagitis grade) and 28 with planning target volume (PTV) overlapping the esophagus. Dose gradients across the esophagus were consistently sharp. Median follow-up and overall survival were 16 and 23 months, respectively. Thirteen patients (25%) developed temporary grade 2 acute esophageal toxicity, 11 (85%) of whom had PTV overlapping the esophagus. Symptoms resolved within 1 to 3 months in 12 patients and 6 months in all patients. No grade 3 to 5 toxicity was observed. Only 3 patients (6%) developed late or persistent grade 2 dysphagia or dyspepsia of uncertain relationship to SABR. The cumulative incidence of acute esophagitis was 15% and 25% at 14 and 60 days, respectively. Acute toxicity correlated on univariate analysis with esophageal D
max , D1cc , D2cc , Dmax /Dprescription , and whether the PTV was overlapping the esophagus. Esophageal Dmax (BED10 ) <62 Gy, D1cc (BED10 ) <48 Gy, D2cc (BED10 ) <43 Gy, and Dmax /Dprescription <85% were associated with <20% risk of grade 2 acute esophagitis. Only 2 local recurrences occurred., Conclusions: Although 25% of patients with tumors near the esophagus developed acute esophagitis (39% of those with PTV overlapping the esophagus), these toxicities were all grade 2 and all temporary. This suggests the safety and efficacy of thoracic SABR for tumors near or abutting the esophagus when treating with high conformity and sharp dose gradients., (Copyright © 2021. Published by Elsevier Inc.)- Published
- 2022
- Full Text
- View/download PDF
36. Ultra-high dose rate electron beams and the FLASH effect: From preclinical evidence to a new radiotherapy paradigm.
- Author
-
Schüler E, Acharya M, Montay-Gruel P, Loo BW Jr, Vozenin MC, and Maxim PG
- Subjects
- Animals, Clinical Protocols, Radiotherapy Dosage, Electrons, Radiotherapy methods
- Abstract
In their seminal paper from 2014, Fauvadon et al. coined the term FLASH irradiation to describe ultra-high-dose rate irradiation with dose rates greater than 40 Gy/s, which results in delivery times of fractions of a second. The experiments presented in that paper were performed with a high-dose-per-pulse 4.5 MeV electron beam, and the results served as the basis for the modern-day field of FLASH radiation therapy (RT). In this article, we review the studies that have been published after those early experiments, demonstrating the robust effects of FLASH RT on normal tissue sparing in preclinical models. We also outline the various irradiation parameters that have been used. Although the robustness of the biological response has been established, the mechanisms behind the FLASH effect are currently under investigation in a number of laboratories. However, differences in the magnitude of the FLASH effect between experiments in different labs have been reported. Reasons for these differences even within the same animal model are currently unknown, but likely has to do with the marked differences in irradiation parameter settings used. Here, we show that these parameters are often not reported, which complicates large multistudy comparisons. For this reason, we propose a new standard for beam parameter reporting and discuss a systematic path to the clinical translation of FLASH RT., (© 2022 American Association of Physicists in Medicine.)
- Published
- 2022
- Full Text
- View/download PDF
37. Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.
- Author
-
Aredo JV, Wakelee HA, Hui AB, Padda SK, Joshi ND, Guo HH, Chaudhuri A, Diehn M, Loo BW Jr, and Neal JW
- Subjects
- Humans, Tyrosine Kinase Inhibitors, ErbB Receptors genetics, Retrospective Studies, Protein Kinase Inhibitors adverse effects, Neoplasm Recurrence, Local drug therapy, Erlotinib Hydrochloride therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
Introduction: Increasing evidence suggests that consolidation durvalumab confers limited benefits for patients with stage III EGFR-mutated NSCLC. Induction or maintenance EGFR tyrosine kinase inhibitors (TKIs) added to concurrent chemoradiotherapy (CRT) may optimize definitive treatment, but there are limited data supporting an induction TKI strategy., Methods: We evaluated the efficacy and safety of induction EGFR TKIs administered before concurrent CRT in a retrospective series of patients with unresectable locally advanced EGFR-mutated NSCLC. Circulating tumor DNA (ctDNA) analysis was performed on a patient subset using CAPP-seq and correlated with outcomes., Results: Of six patients, three received erlotinib and three osimertinib as induction therapy before CRT. Induction TKIs were administered for a median of 2.5 months. The objective response rate after induction TKI was 83%. One patient had a complete response to induction erlotinib and continued erlotinib for 4 years until local progression, which was treated with CRT. Two patients completed maintenance erlotinib after CRT, and another received consolidation durvalumab. After a median follow-up of 20.5 months, only one patient developed disease recurrence, with rising ctDNA coinciding with recurrence. ctDNA remained undetectable in patients without recurrence, or low-level in a patient receiving maintenance erlotinib. Adverse events were mild and expected, and none developed pneumonitis., Conclusion: Induction EGFR TKI before CRT may achieve high disease control rates with promising signs of durability in patients with locally advanced EGFR-mutated NSCLC. ctDNA analysis after CRT can correlate well with clinical outcomes. Prospective studies are needed to define the role of induction EGFR TKIs in this setting., Competing Interests: Declaration of Competing Interest Dr. Aredo reports grants from the Conquer Cancer Foundation of ASCO. Dr. Wakelee reports grants to institution from ACEA Biosciences, Arrys Therapeutics, AztraZeneca/MedImmune, BMS, Celgene, Clovis Oncology, Exelixis, Genentech/Roche, Gilead, Merck, Novartis, Pharmacyclics, Seattle Genetics, Xcovery, Eli Lilly, Pfizer; honoraria from Novartis, AstraZeneca; and is on the advisory boards of AstraZeneca, Xcovery, Janssen, Daiichi Sankyo, Blueprint, Mirati, Helsinn, Merck (uncompensated), Takeda (uncompensated), Genentech/Roche (uncompensated), Cellworks (uncompensated), all outside the submitted work. Dr. Padda reports personal fees from Pfizer, G1 Therapeutics, Blueprint Medicines, AstraZeneca, Abbvie, Janssen Pharmaceuticals; grants to institution from Epicentrx, Bayer, Boehringer Ingelheim, Forty Seven Inc., all outside the submitted work. Dr. Guo reports grants to institution from Pliant Pharmaceuticals; consulting fees from Exact Sciences, BioMind.ai, Arterys, MORE Health; stock from Exact Sciences, all outside the submitted work. Dr. Diehn reports personal fees from Roche, AstraZeneca, Novartis, Genentech, BioNTech, RefleXion, Gritstone Oncology; grants from Varian Medical Systems and AstraZeneca; is on the advisory boards of AstraZeneca, Illumina, Gritstone Oncology, Genentech; other leadership roles of CiberMed, Foresight Diagnostics; non-financial support from Illumina, all outside the submitted work. In addition, Dr. Diehn has a patent related to cancer biomarkers with royalties paid to Roche and Foresight Diagnostics, outside the submitted work. Dr. Loo reports grants from Varian Medical Systems and is a board member of TibaRay, all outside the submitted work. Dr. Neal reports personal fees from Research to Practice, MLI Peerview, Medscape, Biomedical Learning Institute, Prime Oncology, Rockpointe, CME Matters, MJH Life Sciences, AstraZeneca, Jounce Therapeutics, Eli Lilly and Company, Calithera Biosciences, Amgen, Iovance Biotherapeutics, Genentech/Roche, Exelixis, Takeda Pharmaceuticals, UpToDate; grants from Genentech/Roche, Exelixis, Takeda Pharmaceuticals, Merck, Novartis, Boehringer Ingelheim, Nektar Therapeutics, Adaptimmune, GSK, AbbVie, all outside the submitted work. All remaining authors have declared no conflicts of interest., (Copyright © 2022. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
38. Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy.
- Author
-
Benson KRK, Sandhu N, Zhang C, Ko R, Toesca DAS, Lee PE, Von Eyben R, Diehn M, Gensheimer M, Maxim PG, Bush K, Loo BW Jr, Soltys SG, Pollom EL, and Chang DT
- Subjects
- Ablation Techniques, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Retrospective Studies, Colorectal Neoplasms pathology, Colorectal Neoplasms radiotherapy, Metastasectomy methods, Neoplasm Recurrence, Local radiotherapy, Radiosurgery methods
- Abstract
Purpose: The aim of this study was to report local failure (LF) outcomes and associated predictors in patients with oligometastatic colorectal cancer (CRC) treated with stereotactic ablative radiotherapy (SABR)., Materials and Methods: We retrospectively reviewed patients with CRC metastases to the brain, liver, spine, or lung treated with SABR between 2001 and 2016. Time to LF was summarized using cumulative incidence of LF curves with death as a competing risk., Results: The analysis included a total of 130 patients and 256 lesions. Of the metastases treated, 129 (50%) were brain, 50 (20%) liver, 49 (19%) spine, and 28 (11%) lung. Median gross tumor volume was 24 mL for liver metastases, 2 mL for brain metastases, 4 mL for spine metastases, and 1 mL for lung metastases. The overall 1, 2, and 3-year cumulative incidence of LF rates were 21.6% (16.5, 27.1), 28.2% (22.3, 34.4), and 31.5% (25.2, 38.0), respectively. LF was highest among the liver metastases (1 y: 26.0%, 2 y: 38.5%), followed by spine (1 y: 25.1%, 2 y: 31.1%), brain (1 y: 20%, 2 y: 25.2%), and lung (1 y: 13.7%, 2 y: insufficient data). Metastases from right-sided primary CRC were significantly more likely to have LF (P=0.0146, HR=2.23). Biologically effective dose>70 Gy, defined using a standard linear quadratic model using α/β ratio of 10 on the individual lesion level, and pre-SABR chemotherapy were also significant predictors of LF (P= 0.0009 and 0.018, respectively)., Conclusions: CRC metastases treated with SABR had significantly higher rates of LF if they originated from right-sided primary CRC, compared with left-sided. Liver metastases had the highest rates of LF compared with other metastatic sites. Thus, CRC liver metastases and metastases from right-sided CRC may benefit from more aggressive radiotherapy., Competing Interests: S.G.S.: Inovio Pharmaceuticals Inc. (Consultant), Zap Surgical Inc. (Speaker Honoraria), Novocure (Research Funding). B.W.L.Jr: TibaRay (Board member, Cofounder, Stock ownership), Varian Medical Systems (Research funding). E.L.P.: Accuray (Honorarium), Genentech (Research Funding). The remaining authors declare no conflicts of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
39. The Nordic-HILUS Trial: Ultracentral Lung Stereotactic Ablative Radiotherapy and a Narrow Therapeutic Window.
- Author
-
Rosenberg SA, Mak R, Kotecha R, Loo BW Jr, and Senan S
- Subjects
- Humans, Lung, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung surgery, Lung Neoplasms surgery, Radiosurgery
- Published
- 2021
- Full Text
- View/download PDF
40. Radiological tumor classification across imaging modality and histology.
- Author
-
Wu J, Li C, Gensheimer M, Padda S, Kato F, Shirato H, Wei Y, Schönlieb CB, Price SJ, Jaffray D, Heymach J, Neal JW, Loo BW Jr, Wakelee H, Diehn M, and Li R
- Abstract
Radiomics refers to the high-throughput extraction of quantitative features from radiological scans and is widely used to search for imaging biomarkers for prediction of clinical outcomes. Current radiomic signatures suffer from limited reproducibility and generalizability, because most features are dependent on imaging modality and tumor histology, making them sensitive to variations in scan protocol. Here, we propose novel radiological features that are specially designed to ensure compatibility across diverse tissues and imaging contrast. These features provide systematic characterization of tumor morphology and spatial heterogeneity. In an international multi-institution study of 1,682 patients, we discover and validate four unifying imaging subtypes across three malignancies and two major imaging modalities. These tumor subtypes demonstrate distinct molecular characteristics and prognoses after conventional therapies. In advanced lung cancer treated with immunotherapy, one subtype is associated with improved survival and increased tumor-infiltrating lymphocytes compared with the others. Deep learning enables automatic tumor segmentation and reproducible subtype identification, which can facilitate practical implementation. The unifying radiological tumor classification may inform prognosis and treatment response for precision medicine., Competing Interests: Competing interests The authors declare no potential conflicts of interest.
- Published
- 2021
- Full Text
- View/download PDF
41. Multicellular Spheroids as In Vitro Models of Oxygen Depletion During FLASH Irradiation.
- Author
-
Khan S, Bassenne M, Wang J, Manjappa R, Melemenidis S, Breitkreutz DY, Maxim PG, Xing L, Loo BW Jr, and Pratx G
- Subjects
- Humans, Models, Biological, Tumor Hypoxia radiation effects, A549 Cells, Cell Hypoxia physiology, Cell Line, Tumor, Radiation Tolerance, Diffusion, Spheroids, Cellular radiation effects, Oxygen metabolism, Cell Survival radiation effects
- Abstract
Purpose: The differential response of normal and tumor tissues to ultrahigh-dose-rate radiation (FLASH) has raised new hope for treating solid tumors but, to date, the mechanism remains elusive. One leading hypothesis is that FLASH radiochemically depletes oxygen from irradiated tissues faster than it is replenished through diffusion. The purpose of this study was to investigate these effects within hypoxic multicellular tumor spheroids through simulations and experiments., Methods and Materials: Physicobiological equations were derived to model (1) the diffusion and metabolism of oxygen within spheroids; (2) its depletion through reactions involving radiation-induced radicals; and (3) the increase in radioresistance of spheroids, modeled according to the classical oxygen enhancement ratio and linear-quadratic response. These predictions were then tested experimentally in A549 spheroids exposed to electron irradiation at conventional (0.075 Gy/s) or FLASH (90 Gy/s) dose rates. Clonogenic survival, cell viability, and spheroid growth were scored postradiation. Clonogenic survival of 2 other cell lines was also investigated., Results: The existence of a hypoxic core in unirradiated tumor spheroids is predicted by simulations and visualized by fluorescence microscopy. Upon FLASH irradiation, this hypoxic core transiently expands, engulfing a large number of well-oxygenated cells. In contrast, oxygen is steadily replenished during slower conventional irradiation. Experimentally, clonogenic survival was around 3-fold higher in FLASH-irradiated spheroids compared with conventional irradiation, but no significant difference was observed for well-oxygenated 2-dimensional cultured cells. This differential survival is consistent with the predictions of the computational model. FLASH irradiation of spheroids resulted in a dose-modifying factor of around 1.3 for doses above 10 Gy., Conclusions: Tumor spheroids can be used as a model to study FLASH irradiation in vitro. The improved survival of tumor spheroids receiving FLASH radiation confirms that ultrafast radiochemical oxygen depletion and its slow replenishment are critical components of the FLASH effect., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
42. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
- Author
-
Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW Jr, Diehn M, Han SS, and Wakelee HA
- Subjects
- Antibodies, Monoclonal, Chemoradiotherapy, ErbB Receptors genetics, ErbB Receptors therapeutic use, Humans, Neoplasm Recurrence, Local, Retrospective Studies, Lung Neoplasms drug therapy, Lung Neoplasms therapy
- Abstract
Introduction: In 2018, durvalumab was approved by the U.S. Food and Drug Administration as consolidation immunotherapy for patients with stage III NSCLC after definitive chemoradiotherapy (CRT). However, whether durvalumab benefits patients with EGFR-mutated NSCLC remains unknown., Methods: We conducted a multi-institutional retrospective analysis of patients with unresectable stage III EGFR-mutated NSCLC who completed concurrent CRT. Kaplan-Meier analyses evaluated progression-free survival (PFS) between patients who completed CRT with or without durvalumab., Results: Among 37 patients, 13 initiated durvalumab a median of 20 days after CRT completion. Two patients completed 12 months of treatment, with five patients discontinuing durvalumab owing to progression and five owing to immune-related adverse events (irAEs). Of 24 patients who completed CRT without durvalumab, 16 completed CRT alone and eight completed CRT with induction or consolidation EGFR tyrosine kinase inhibitors (TKIs). Median PFS was 10.3 months in patients who received CRT and durvalumab versus 6.9 months with CRT alone (log-rank p = 0.993). CRT and EGFR TKI was associated with a significantly longer median PFS (26.1 mo) compared with CRT and durvalumab or CRT alone (log-rank p = 0.023). Six patients treated with durvalumab initiated EGFR TKIs after recurrence, with one developing grade 4 pneumonitis on osimertinib., Conclusions: In this study, patients with EGFR-mutated NSCLC did not benefit with consolidation durvalumab and experienced a high frequency of irAEs. Patients who initiate osimertinib after durvalumab may be susceptible to incident irAEs. Consolidation durvalumab should be approached with caution in this setting and concurrent CRT with induction or consolidation EGFR TKIs further investigated as definitive treatment., (Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
43. Constrained by Constraints, or Manacled by Margin Mandates?
- Author
-
Loo BW Jr and Pham D
- Published
- 2021
- Full Text
- View/download PDF
44. Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
- Author
-
Lee P, Loo BW Jr, Biswas T, Ding GX, El Naqa IM, Jackson A, Kong FM, LaCouture T, Miften M, Solberg T, Tome WA, Tai A, Yorke E, and Li XA
- Subjects
- Carcinoma, Non-Small-Cell Lung diagnostic imaging, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Cause of Death, Dose-Response Relationship, Radiation, Follow-Up Studies, Humans, Lung Neoplasms diagnostic imaging, Lung Neoplasms mortality, Lung Neoplasms pathology, Models, Biological, Models, Theoretical, Neoplasm Recurrence, Local diagnostic imaging, Probability, Radiotherapy Planning, Computer-Assisted, Time Factors, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms radiotherapy, Radiosurgery methods
- Abstract
Purpose: Numerous dose and fractionation schedules have been used to treat medically inoperable stage I non-small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy. We evaluated published experiences with SBRT to determine local control (LC) rates as a function of SBRT dose., Methods and Materials: One hundred sixty published articles reporting LC rates after SBRT for stage I NSCLC were identified. Quality of the series was assessed by evaluating the number of patients in the study, homogeneity of the dose regimen, length of follow-up time, and reporting of LC. Clinical data including 1, 2, 3, and 5-year tumor control probabilities for stages T1, T2, and combined T1 and T2 as a function of the biological effective dose were fitted to the linear quadratic, universal survival curve, and regrowth models., Results: Forty-six studies met inclusion criteria. As measured by the goodness of fit χ
2 /ndf, with ndf as the number of degrees of freedom, none of the models were ideal fits for the data. Of the 3 models, the regrowth model provides the best fit to the clinical data. For the regrowth model, the fitting yielded an α-to-β ratio of approximately 25 Gy for T1 tumors, 19 Gy for T2 tumors, and 21 Gy for T1 and T2 combined. To achieve the maximal LC rate, the predicted physical dose schemes when prescribed at the periphery of the planning target volume are 43 ± 1 Gy in 3 fractions, 47 ± 1 Gy in 4 fractions, and 50 ± 1 Gy in 5 fractions for combined T1 and T2 tumors., Conclusions: Early-stage NSCLC is radioresponsive when treated with SBRT or stereotactic ablative radiation therapy. A steep dose-response relationship exists with high rates of durable LC when physical doses of 43-50 Gy are delivered in 3 to 5 fractions., (Copyright © 2019 Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
45. An automated optimization strategy to design collimator geometry for small field radiation therapy systems.
- Author
-
Wang J, Wang L, Maxim PG, and Loo BW Jr
- Subjects
- Monte Carlo Method, Particle Accelerators, Radiometry, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted methods, Radiosurgery methods
- Abstract
Purpose . To develop an automated optimization strategy to facilitate collimator design for small-field radiotherapy systems. Methods and Materials. We developed an objective function that links the dose profile characteristics (FWHM, penumbra, and central dose rate) and the treatment head geometric parameters (collimator thickness/radii, source-to-distal-collimator distance (SDC)) for small-field radiotherapy systems. We performed optimization using a downhill simplex algorithm. We applied this optimization strategy to a linac-based radiosurgery system to determine the optimal geometry of four pencil-beam collimators to produce 5, 10, 15, and 20 mm diameter photon beams (from a 6.7 MeV, 2.1 mm FWHM electron beam). Two different optimizations were performed to prioritize minimum penumbra or maximum central dose rate for each beam size. We compared the optimized geometric parameters and dose distributions to an existing clinical system (CyberKnife). Results. When minimum penumbra was prioritized, using the same collimator thickness and SDC (40 cm) as a CyberKnife system, the optimized collimator upstream and downstream radii agreed with the CyberKnife system within 3%-14%, the optimized output factors agreed within 0%-8%, and the optimized transverse and percentage depth dose profiles matched those of the CyberKnife with the penumbras agreeing within 2%. However, when maximum dose rate was prioritized, allowing both the collimator thickness and SDC to change, the central dose rate for larger collimator sizes (10, 15, 20 mm) could be increased by about 1.5-2 times at the cost of 1.5-2 times larger penumbras. No further improvement in central dose rate for the 5 mm beam size could be achieved. Conclusions. We developed an automated optimization strategy to design the collimator geometry for small-field radiation therapy systems. Using this strategy, the penumbra-prioritized dose distribution and geometric parameters agree well with the CyberKnife system as an example, suggesting that this system was designed to prioritize sharp penumbra. This represents proof-of-principle that an automated optimization strategy may apply to more complex collimator designs with multiple optimization parameters., (© 2021 Institute of Physics and Engineering in Medicine.)
- Published
- 2021
- Full Text
- View/download PDF
46. Effects of Ultra-high doserate FLASH Irradiation on the Tumor Microenvironment in Lewis Lung Carcinoma: Role of Myosin Light Chain.
- Author
-
Kim YE, Gwak SH, Hong BJ, Oh JM, Choi HS, Kim MS, Oh D, Lartey FM, Rafat M, Schüler E, Kim HS, von Eyben R, Weissman IL, Koch CJ, Maxim PG, Loo BW Jr, and Ahn GO
- Subjects
- Animals, Azepines administration & dosage, Blood Vessels pathology, Blood Vessels radiation effects, CD8-Positive T-Lymphocytes cytology, Carcinoma, Lewis Lung blood supply, Carcinoma, Lewis Lung metabolism, Histones metabolism, Histones radiation effects, Male, Mice, Mice, Inbred C57BL, Myosin Light Chains antagonists & inhibitors, Myosin Light Chains metabolism, Naphthalenes administration & dosage, Platelet Endothelial Cell Adhesion Molecule-1 metabolism, Platelet Endothelial Cell Adhesion Molecule-1 radiation effects, Radiotherapy methods, Radiotherapy Dosage, Reactive Oxygen Species metabolism, Reactive Oxygen Species radiation effects, Carcinoma, Lewis Lung radiotherapy, Myosin Light Chains radiation effects, Tumor Microenvironment radiation effects
- Abstract
Purpose: To investigate whether the vascular collapse in tumors by conventional dose rate (CONV) irradiation (IR) would also occur by the ultra-high dose rate FLASH IR., Methods and Materials: Lewis lung carcinoma (LLC) cells were subcutaneously implanted in mice. This was followed by CONV or FLASH IR at 15 Gy. Tumors were harvested at 6 or 48 hours after IR and stained for CD31, phosphorylated myosin light chain (p-MLC), γH2AX (a surrogate marker for DNA double strand break), intracellular reactive oxygen species (ROS), or immune cells such as myeloid and CD8α T cells. Cell lines were irradiated with CONV IR for Western blot analyses. ML-7 was intraperitoneally administered daily to LLC-bearing mice for 7 days before 15 Gy CONV IR. Tumors were similarly harvested and analyzed., Results: By immunostaining, we observed that CONV IR at 6 hours resulted in constricted vessel morphology, increased expression of p-MLC, and much higher numbers of γH2AX-positive cells in tumors, which were not observed with FLASH IR. Mechanistically, MLC activation by ROS is unlikely, because FLASH IR produced significantly more ROS than CONV IR in tumors. In vitro studies demonstrated that ML-7, an inhibitor of MLC kinase, abrogated IR-induced γH2AX formation and disappearance kinetics. Lastly, we observed that CONV IR when combined with ML-7 produced some effects similar to FLASH IR, including reduction in the vasculature collapse, fewer γH2AX-positive cells, and increased immune cell influx to the tumors., Conclusions: FLASH IR produced novel changes in the tumor microenvironment that were not observed with CONV IR. We believe that MLC activation in tumors may be responsible for some of the microenvironmental changes differentially regulated between CONV and FLASH IR., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
47. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
- Author
-
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dowell J, Gettinger S, Gubens MA, Hegde A, Hennon M, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW Jr, Lovly CM, Martins RG, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Riely GJ, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Yanagawa J, Yang SC, Gregory KM, and Hughes M
- Subjects
- Biomarkers, Tumor, Humans, Immunotherapy, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung therapy, Lung Neoplasms diagnosis, Lung Neoplasms therapy
- Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.
- Published
- 2021
- Full Text
- View/download PDF
48. Abdominal FLASH irradiation reduces radiation-induced gastrointestinal toxicity for the treatment of ovarian cancer in mice.
- Author
-
Levy K, Natarajan S, Wang J, Chow S, Eggold JT, Loo PE, Manjappa R, Melemenidis S, Lartey FM, Schüler E, Skinner L, Rafat M, Ko R, Kim A, H Al-Rawi D, von Eyben R, Dorigo O, Casey KM, Graves EE, Bush K, Yu AS, Koong AC, Maxim PG, Loo BW Jr, and Rankin EB
- Subjects
- Animals, Female, Gastrointestinal Tract injuries, Gastrointestinal Tract pathology, Mice, Mice, Inbred C57BL, Radiotherapy adverse effects, Gastrointestinal Tract radiation effects, Ovarian Neoplasms radiotherapy, Radiation Injuries, Experimental prevention & control, Radiotherapy methods
- Abstract
Radiation therapy is the most effective cytotoxic therapy for localized tumors. However, normal tissue toxicity limits the radiation dose and the curative potential of radiation therapy when treating larger target volumes. In particular, the highly radiosensitive intestine limits the use of radiation for patients with intra-abdominal tumors. In metastatic ovarian cancer, total abdominal irradiation (TAI) was used as an effective postsurgical adjuvant therapy in the management of abdominal metastases. However, TAI fell out of favor due to high toxicity of the intestine. Here we utilized an innovative preclinical irradiation platform to compare the safety and efficacy of TAI ultra-high dose rate FLASH irradiation to conventional dose rate (CONV) irradiation in mice. We demonstrate that single high dose TAI-FLASH produced less mortality from gastrointestinal syndrome, spared gut function and epithelial integrity, and spared cell death in crypt base columnar cells compared to TAI-CONV irradiation. Importantly, TAI-FLASH and TAI-CONV irradiation had similar efficacy in reducing tumor burden while improving intestinal function in a preclinical model of ovarian cancer metastasis. These findings suggest that FLASH irradiation may be an effective strategy to enhance the therapeutic index of abdominal radiotherapy, with potential application to metastatic ovarian cancer.
- Published
- 2020
- Full Text
- View/download PDF
49. KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition.
- Author
-
Binkley MS, Jeon YJ, Nesselbush M, Moding EJ, Nabet BY, Almanza D, Kunder C, Stehr H, Yoo CH, Rhee S, Xiang M, Chabon JJ, Hamilton E, Kurtz DM, Gojenola L, Owen SG, Ko RB, Shin JH, Maxim PG, Lui NS, Backhus LM, Berry MF, Shrager JB, Ramchandran KJ, Padda SK, Das M, Neal JW, Wakelee HA, Alizadeh AA, Loo BW Jr, and Diehn M
- Subjects
- Humans, Lung Neoplasms pathology, Mutation, Biomarkers metabolism, Glutaminase antagonists & inhibitors, Kelch-Like ECH-Associated Protein 1 metabolism, Lung Neoplasms genetics, NF-E2-Related Factor 2 metabolism, Radiation Tolerance drug effects
- Abstract
Tumor genotyping is not routinely performed in localized non-small cell lung cancer (NSCLC) due to lack of associations of mutations with outcome. Here, we analyze 232 consecutive patients with localized NSCLC and demonstrate that KEAP1 and NFE2L2 mutations are predictive of high rates of local recurrence (LR) after radiotherapy but not surgery. Half of LRs occurred in tumors with KEAP1/NFE2L2 mutations, indicating that they are major molecular drivers of clinical radioresistance. Next, we functionally evaluate KEAP1/NFE2L2 mutations in our radiotherapy cohort and demonstrate that only pathogenic mutations are associated with radioresistance. Furthermore, expression of NFE2L2 target genes does not predict LR, underscoring the utility of tumor genotyping. Finally, we show that glutaminase inhibition preferentially radiosensitizes KEAP1 -mutant cells via depletion of glutathione and increased radiation-induced DNA damage. Our findings suggest that genotyping for KEAP1/NFE2L2 mutations could facilitate treatment personalization and provide a potential strategy for overcoming radioresistance conferred by these mutations. SIGNIFICANCE: This study shows that mutations in KEAP1 and NFE2L2 predict for LR after radiotherapy but not surgery in patients with NSCLC. Approximately half of all LRs are associated with these mutations and glutaminase inhibition may allow personalized radiosensitization of KEAP1/NFE2L2 -mutant tumors. This article is highlighted in the In This Issue feature, p. 1775 ., (©2020 American Association for Cancer Research.)
- Published
- 2020
- Full Text
- View/download PDF
50. Resection following concurrent chemotherapy and high-dose radiation for stage IIIA non-small cell lung cancer.
- Author
-
Donington JS, Paulus R, Edelman MJ, Krasna MJ, Le QT, Suntharalingam M, Loo BW Jr, Hu C, and Bradley JD
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Chemoradiotherapy adverse effects, Female, Humans, Male, Middle Aged, Postoperative Complications epidemiology, Postoperative Complications mortality, Retrospective Studies, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung therapy, Lung Neoplasms pathology, Lung Neoplasms therapy, Pneumonectomy adverse effects, Pneumonectomy mortality
- Abstract
Objective: Concern exists regarding surgery after thoracic radiation. We aimed to assess early results of anatomic resection following induction therapy with platinum-based chemotherapy and full-dose thoracic radiation for resectable N2+ stage IIIA non-small cell lung cancer., Methods: Two prospective trials were recently conducted by NRG Oncology in patients with resectable N2+ stage IIIA non-small cell lung cancer with the primary end point of mediastinal node sterilization following concurrent full-dose chemoradiotherapy (Radiation Therapy Oncology Group trials 0229 and 0839). All surgeons demonstrated postinduction resection expertise. Induction consisted of weekly carboplatin (area under the curve, 2.0) and paclitaxel (50 mg/m
2 ) and concurrent thoracic radiation 60 Gy (0839)/61.2 Gy (0229) in 30 fractions. Patients in study 0839 were randomized 2:1 to weekly panitumumab + chemoradiotherapy or chemoradiotherapy alone during induction. Primary results were similar in all treatment arms and reported previously. Short-term surgical outcomes are reported here., Results: One hundred twenty-six patients enrolled; 93 (74%) had anatomic resection, 77 underwent lobectomy, and 16 underwent extended resection. Microscopically margin-negative resections occurred in 85 (91%). Fourteen (15%) resections were attempted minimally invasively, including 2 converted without event. Grade 3 or 4 surgical adverse events were reported in 26 (28%), 30-day mortality in 4 (4%) and 90-day mortality in 5 (5%). Patients undergoing extended resection experienced similar rates of grade 3 or 4 adverse events (odds ratio, 0.95; 95% confidence interval, 0.42-3.8) but higher 30-day (1.3% vs 18.8%) (odds ratio, 17.54; 95% confidence interval, 1.75-181.8) and 90-day mortality (2.6% vs 18.8%) (odds ratio, 8.65; 95% confidence interval, 1.3-56.9)., Conclusions: Lobectomy was performed safely following full-dose concurrent chemoradiotherapy in these multi-institutional prospective trials; however, increased mortality was noted with extended resections., (Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.